Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.1.1.45 - thymidylate synthase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Direct Reprogramming of Mouse Embryonic Fibroblasts to Induced Trophoblast Stem Cells.
Abortion, Spontaneous
Effect of methylenetetrahydrofolate reductase and thymidylate synthase enhancer region polymorphisms on the risk of idiopathic recurrent spontaneous abortion in a Korean population.
Influence of combined methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase enhancer region (TSER) polymorphisms to plasma homocysteine levels in Korean patients with recurrent spontaneous abortion.
Acquired Immunodeficiency Syndrome
The crystal structure of thymidylate synthase from Pneumocystis carinii reveals a fungal insert important for drug design.
Adenocarcinoma
A pilot study to investigate the role of thymidylate synthase as a marker of prognosis for neoadjuvant chemotherapy in gastric and gastro-oesophageal junction adenocarcinoma.
A unique case of a patient with rectal cancer who developed benign esophageal stenosis after localized rectal radiation and systemic chemotherapy.
Activity of thymidylate synthetase and its inhibition by 5-fluorouracil in highly enzyme-overproducing cells resistant to 10-propargyl-5,8-dideazafolate.
AraC-FdUMP[10] (CF10) is a next generation fluoropyrimidine with potent antitumor activity in PDAC and synergy with PARG inhibition.
Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma.
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.
Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, ZD1694 and AG-331.
Correlation between histological differentiation and DNA-synthesizing enzymes in rat colorectal tumors induced with 1, 2-dimethylhydrazine.
Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas.
Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed.
Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung.
Effects of 5-fluorouracil derivative UFT on thymidylate synthetase and thymidine kinase in rat colorectal tumors.
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.
Expression of thymidylate synthase in human gastric and colorectal adenocarcinomas is upregulated by p16/INK4.
Expression of thymidylate synthase in primary colorectal adenocarcinoma.
Gene dosage and expression, and enzyme activity of thymidine kinase and thymidylate synthase in xenografted colorectal adenocarcinomas.
Gene polymorphisms involved in folate and methionine metabolism and increased risk of sporadic colorectal adenocarcinoma.
Genetic heterogeneity of variable number tandem repeats in thymidylate synthase gene in colorectal cancer patients.
High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.
Histologic subtype in NSCLC: does it matter?
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines.
Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.
Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells.
Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.
Leucovorin and folic acid regimens for selective expansion of murine 5,10-methylenetetrahydrofolate pools.
Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Mutation(s) of the thymidylate synthase gene of human adenocarcinoma cells causes a thymidylate synthase-negative phenotype that can be attenuated by exogenous folates.
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer.
Polymorphism at the 3'-UTR of the thymidylate synthase gene: A potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation.
Predictors of response and survival for neoadjuvant treated patients with esophageal adenocarcinoma.
Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection.
Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy.
Prognostic significance of thymidylate synthase expression in pancreatic adenocarcinoma: A meta-analysis.
Prognostic value of p21-activated kinase 4 in resected pancreatic cancer.
Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung.
Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma.
Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung.
Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues.
The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts.
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population.
Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.
Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma.
Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy.
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients.
Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma.
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations.
Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor.
Updated clinical information on multitargeted antifolates in lung cancer.
[A Recurrent Case of Thymic Adenocarcinoma Effectively Treated with S-1 Over a Long-Term Period].
[The evaluation of cellular proliferating activity in gastric carcinoma with the proliferating cell nuclear antigen (PCNA) expressive rate: its fundamental examination of the immunohistochemical procedures and its clinical applications]
Adenocarcinoma of Lung
Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression.
Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach.
Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma.
Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients.
The influence of methylenetetrahydrofolate reductase and thymidylate synthetase gene polymorphisms on lung adenocarcinoma occurrence.
Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
TS expression predicts postoperative recurrence in adenocarcinoma of the lung.
[Thymidylate synthase expression and therapeutic effect analysis of pemetrexed in advanced lung adenocarcinoma]
Adenoma
Dietary intake of B-vitamins, polymorphisms in thymidylate synthase and serine hydroxymethyltransferase 1, and colorectal adenoma risk: a Dutch case-control study.
Methionine synthase and thymidylate synthase gene polymorphisms and colorectal adenoma risk: The self defense forces study.
Polymorphism in the thymidylate synthase promoter enhancer region and risk of colorectal adenomas.
Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma.
Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas.
Adenomyosis
Effects of conjugated estrogens with or without medroxyprogesterone acetate on mammary carcinogenesis, uterine adenomyosis and femur in mice.
Suppression of spontaneous development of uterine adenomyosis by a Chinese herbal medicine, keishi-bukuryo-gan, in mice.
Adrenal Cortex Neoplasms
Topoisomerase 2? and thymidylate synthase expression in adrenocortical cancer.
Anemia
Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival.
Anemia, Pernicious
Letter: Thymidylate synthetase in pernicious anemia.
Thymidylate synthetase activity in bone marrow cells in pernicious anemia.
Thymidylate synthetase in pernicious anemia. I.
Thymidylate synthetase in pernicious anemia. II.
Arachnoid Cysts
Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.
Arthritis
Pharmacogenetic study of 5,10-methylenetetrahydrofolate reductase C677T and thymidylate synthase 3R/2R gene polymorphisms and methotrexate-related toxicity in Chinese Han patients with inflammatory arthritis.
Arthritis, Rheumatoid
Are Thymidylate synthase and Methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients?
Association of hyperhomocysteinemia with genetic variants in key enzymes of homocysteine metabolism and methotrexate toxicity in rheumatoid arthritis patients.
Effect of thymidylate synthase (TYMS) gene polymorphisms with methotrexate treatment outcome in south Indian Tamil patients with rheumatoid arthritis.
Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs.
Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences.
Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.
Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis.
Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.
TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis.
[Thymidylate synthase genetic polymorphism and plasma total homocysteine level in a group of Turkish patients with rheumatoid arthritis: relationship with disease activity and methotrexate toxicity.]
Ataxia Telangiectasia
P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting.
Bacterial Infections
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Biliary Tract Neoplasms
Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
Brain Infarction
The 3'-UTR Polymorphisms in the Thymidylate Synthase (TS) Gene Associated with the Risk of Ischemic Stroke and Silent Brain Infarction.
Brain Neoplasms
Experimental combination chemotherapy with thymidylate synthetase and ribonucleotide reductase inhibitors.
Polymorphisms of Folate Pathway Enzymes (Methylenetetrahydrofolate Reductase and Thymidylate Synthase) and Their Relationship with Thymidylate Synthase Expression in Human Astrocytic Tumors.
Breast Neoplasms
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
Anti-Cancer Effect of IN-2001 in T47D Human Breast Cancer.
Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2?positive breast cancer.
Association between polymorphisms in the thymidylate synthase gene and risk of breast cancer in a Mexican population.
Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA.
Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.
BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin.
Chapter 4 molecular mechanisms of adaptation to folate deficiency.
Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer.
Clinicopathological stages and pyrimidine nucleotide synthesis in human mammary carcinomas.
Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
Diagnostic and prognostic value of thymidylate synthase expression in breast cancer.
Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients.
Difference in thymidylate synthetase activity in involved nodes compared with primary tumor in breast cancer patients.
Different expression of thymidylate synthase in primary tumour and metastatic nodes in breast cancer patients.
DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients.
Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S]leucovorin combination therapy for breast cancer.
Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates.
Evaluation of sensitivity to 5-FU on the basis of thymidylate synthase (TS)/dihydropyrimidine dehydrogenase (DPD) activity and chromosomal analysis in micro tissue specimens of breast cancer.
Evaluation of thymidylate synthase RNA expression by polymerase chain reaction.
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic.
Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, ?-tubulin III, thymidylate synthetase, and topoisomerase II? in breast cancer: Association with clinicopathological characteristics.
Free circulating mRNA in plasma from breast cancer patients and clinical outcome.
Functional polymorphism of thymidylate synthase, but not of the COMT and IL-1B genes, is associated with breast cancer.
Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study.
Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells.
Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.
Methylenetetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype.
Pemetrexed: translational research in breast cancer.
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer.
Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis.
Polymorphisms of one-carbon-metabolizing genes and risk of breast cancer in a population-based study.
Prognostic importance of thymidylate synthase expression in early breast cancer.
Proteomics of Sentinel Lymph Nodes in Early Breast Cancer for Identification of Thymidylate Synthase as a Potential Biomarker to Flag Metastasis: A Preliminary Study.
Relationship between thymidylate synthase (TYMS) gene polymorphism and TYMS protein levels in patients with high-risk breast cancer.
Relationship between thymidylate synthase and p53 and response to FEC versus taxane adjuvant chemotherapy for breast carcinoma.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.
The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer.
Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
Thymidine labeling index of human breast carcinoma. Enhancement of in vitro labeling by 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer.
Thymidylate synthase gene polymorphisms effecting 5-FU response in breast cancer patients.
Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer.
Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers.
Thymidylate synthase predicts for clinical outcome in invasive breast cancer.
Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer.
Transcriptional Activation of Thymidylate Synthase by 17?-Estradiol in MCF-7 Human Breast Cancer Cells.
Transcriptional activation of thymidylate synthase by 17beta-estradiol in MCF-7 human breast cancer cells.
Translational research with pemetrexed in breast cancer.
[A preliminary study on dihydropyrimidine dehydrogenase activity in breast cancer]
[Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer]
[Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis.]
[Relationships among the expression of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase and the prognosis of breast cancer]
[Significance of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) activity in breast cancer tissue]
[Significance of tissue PyNPase, TS, and DPD activities in breast cancer]
[Standardization and quality control in the evaluation of proliferation parameters in T1T2, N0N1, M0 breast cancer : multicentric retrospective study I. DNA synthesis enzyme activities]
[Standardization and quality control in the evaluation of proliferation parameters in T1T2, N0N1, M0 breast cancer: multicentric retrospective study II. DNA-ploidy and S-phase fraction]
Carcinogenesis
Effects of conjugated estrogens with or without medroxyprogesterone acetate on mammary carcinogenesis, uterine adenomyosis and femur in mice.
Effects of long-term administration of UFT plus leucovorin on colorectal tumors induced with 1,2-dimethylhydrazine in rats.
Folate-related nutrients, genetic polymorphisms, and colorectal cancer risk: the fukuoka colorectal cancer study.
Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival.
Carcinoma
5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
5-Fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase.
7-Hydro-8-methylpteroylglutamylglutamic acid, a new anti-folate from an actinomycete. Fermentation, isolation, structure and biological activity.
A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma.
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
Acyclic analogues of 5-fluoro-dUMP and 5-fluoro-2'-deoxyuridine: synthesis and inhibition of thymidylate synthase and tumour cell growth.
Altered thymidylate synthetase in 5-fluorodeoxyuridine-resistant Ehrlich ascites carcinoma cells.
Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes.
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Antitumour effects of pure diastereoisomers of 5-formyltetrahydrofolate in hepatic transplants of a rodent colon carcinoma model.
Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma.
Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil.
Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma.
Associations between gene polymorphisms of thymidylate synthase with its protein expression and chemosensitivity to 5-fluorouracil in pancreatic carcinoma cells.
AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.
Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid.
Calcium and calcium sensing receptor modulates the expression of thymidylate synthase, NAD(P)H:quinone oxidoreductase 1 and survivin in human colon carcinoma cells: Promotion of cytotoxic response to mitomycin C and fluorouracil.
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Characterization of the effect of AG337, a novel lipophilic thymidylate synthase inhibitor, on human head and neck and human leukemia cell lines.
Clinical relevance of thymidylate synthase (TS) activity for S-1-based chemotherapy in squamous cell carcinoma of the oral cavity.
Clinical value of thymidine kinase in patients with cervical carcinoma.
Clinicopathological stages and pyrimidine nucleotide synthesis in human mammary carcinomas.
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinoma.
Comparison of the mRNA expression of factors related to drug resistance in lung tumors and adjacent normal tissue.
Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2'-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver.
Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations.
Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity.
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil.
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung.
DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
Down-regulation of c-myc gene expression with induction of high molecular weight DNA fragments by fluorodeoxyuridine.
Effect of Uridine on the Metabolism of 5-Fluorouracil in the CD8F 1 Murine Mammary Carcinoma System.
Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Effects of kampo (Japanese herbal) medicine "sho-saiko-to" on DNA-synthesizing enzyme activity in 1,2-dimethylhydrazine-induced colonic carcinomas in rats.
Effects of Mg2+ and adenine nucleotides on thymidylate synthetase from different mouse tumors.
Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma.
Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.
Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.
Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas.
Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery.
Establishment of mutant FM3A murine mammary carcinoma cell strains transformed with the herpes simplex virus type 1 thymidine kinase gene.
Evaluation of thymidylate synthase protein expression by Western blotting and immunohistochemistry on human colon carcinoma xenografts in nude mice.
Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma.
Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study.
Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis.
Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome.
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in adenoid cystic carcinoma of the head and neck: correlation with clinical outcome.
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome.
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82.
Expression of thymidylate synthase and glutathione-s-transferase pi in patients with esophageal squamous cell carcinoma.
Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits.
Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, ?-tubulin III, thymidylate synthetase, and topoisomerase II? in breast cancer: Association with clinicopathological characteristics.
FLUORINATED PYRIMIDINES. XXV. THE INHIBITION OF THYMIDYLATE SYNTHETASE FROM EHRLICH ASCITES CARCINOMA CELLS BY PYRIMIDINE ANALOGS.
Genetic polymorphisms in folate- metabolizing enzymes and risk of gastroesophageal cancers: a potential nutrient-gene interaction in cancer development.
Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy.
High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.
High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes.
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
Immunohistochemical analysis of thymidylate synthase expression in gastric carcinoma: correlation with clinicopathological parameters and survival.
Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines.
Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness.
Impact of intratumoral thymidylate synthase expression on prognosis after surgical resection for ampullary carcinoma.
Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma.
Increased thymidylate synthase (EC 2.1.1.45) activity in normal and neoplastic proliferation.
Inhibition of apoptosis after thymineless stress is conferred by oncogenic K-Ras in colon carcinoma cells.
Inhibition of mammalian tumour thymidylate synthetase by 2'-deoxyuridine 5'-phosphate analogues.
Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat.
Inhibition of thymidylate synthetase of Walker carcinoma by chlorambucil. A possible mechanism of action.
Interaction between Gambogic acid and dihydrofolate reductase and synergistic lethal effects with methotrexate on hepatoma cells.
Interferon alpha-2a shows antitumor activity in combination with 5-fluorouracil against human colon carcinoma xenografts: a study in reference to thymidylate synthetase activity inhibition.
Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Intratumoural expression of thymidylate synthase is an independent predictor of prognosis in patients with squamous cell carcinoma of the tongue: results from a retrospective study.
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.
Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues.
Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.
Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Mechanism of inhibition of mammalian tumor and other thymidylate synthases by N4-hydroxy-dCMP, N4-hydroxy-5-fluoro-dCMP, and related analogues.
Methotrexate decreases thymidine kinase activity.
Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides.
Modulation of target enzyme associated with the action of antifolates.
Nifedipine synergizes with calcium in activating the calcium sensing receptor, suppressing the expression of thymidylate synthase and survivin and promoting sensitivity to fluorouracil in human colon carcinoma cells.
P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells.
Pathological features and pyrimidine nucleotide synthesis in human gastric carcinomas.
Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer.
Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase in squamous cell carcinoma and basal cell carcinoma of the skin.
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
Predictive value of immunohistochemical thymidylate synthase expression for histological response to Tegafur/Uracil (UFT) in oral squamous cell carcinoma.
Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
Prognostic significance of thymidylate synthase activity in bladder carcinoma.
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Properties of thymidylate synthetase from Ehrlich ascites carcinoma cells. Effect of Mg2/ and MgATP2-.
Protein Expression Profiles Indicative for Drug Resistance of Kidney Carcinoma.
Purification and properties of mouse thymus thymidylate synthase. Comparison of the enzyme from mammalian normal and tumour tissues.
Purification of thymidylate synthetase from Ehrlich ascites carcinoma cells.
Quantification of thymidylate synthase gene expression in human gastrointestinal carcinoma tissues using competitive PCR.
Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization.
Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method.
Relationship between immunohistochemical evaluation of thymidylate synthase and proliferating cell nuclear antigen labeling index in gastrointestinal carcinoma.
Relative activities of thymidylate synthetase and thymidine kinase in 1,2-dimethylhydrazine-induced colon carcinomas in rats.
Relative level of thymidylate synthase mRNA expression in primary tumors and normal tissues predicts survival of patients with oral tongue squamous cell carcinoma.
Resistance mechanisms and their regulation in lung cancer.
Resistance to methotrexate in thymidylate synthetase-deficient mutants of cultured mouse mammary tumor FM3A cells.
Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma.
Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma.
Significance of thymidine kinase activity in renal cell carcinoma.
Significance of thymidylate synthase activity in renal cell carcinoma.
Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
The combined-action of ici-d1694, 5-fluoro-2'-deoxyuridine and 5-Fluorouracil in inhibiting the growth of a human renal-cell carcinoma cell-line (rpmi-se) in-vitro.
The effect of cyclic nucleotides on DNA polymerase, thymidylate synthetase, thymidine kinase and deoxynucleoside levels of Waler carcinoma.
The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
The potentiation of radiation response in human colon carcinoma cells in vitro and murine lymphoma in vivo by AG337 (Thymitaq), a novel thymidylate synthase inhibitor.
The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck.
The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhibited cells.
Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
Thymidylate synthase 1 (ts1) in-situ protein expression predicts the survival of ewing/pnet.
Thymidylate synthase 5'- and 3'-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck.
Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues.
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study.
Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer.
Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.
Thymidylate synthase expression as a predictor of clinical response to 5-fluorouracil-based chemoradiotherapy in patients with maxillary sinus squamous cell carcinoma.
Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial.
Thymidylate synthase expression in colon carcinomas with microsatellite instability.
Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.
Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations.
Thymidylate synthetase allelic imbalance in clear cell renal carcinoma.
Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer.
Thymidylate synthetase and thymidine kinase activities in DMH-induced colon carcinomas in rats and effects of UFT.
Thymidylate synthetase-positive and -negative murine mammary FM3A carcinoma cells as a useful system for detecting thymidylate synthetase inhibitors.
Thymineless death in colon carcinoma cells is mediated via fas signaling.
Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: Downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU.
Where should the specimen be excised for the chemosensitivity of colorectal cancer to 5-fluorouracil?
[Assessment of dihydropyrimidine dehydrogenase and thymidylate synthase expression in gastric carcinoma and colonic carcinoma]
[Association of thymidylate synthase polymorphism with esophageal squamous-cell carcinoma]
[Development of new treatment modalities for advanced head and neck carcinomas]
[Dihydropyrimidine dehydrogenase and thymidylate synthase in colon carcinoma]
[Effects of hyperthermochemotherapy on activities of DNA-synthesizing enzymes in 1, 2-dimethylhydrazine (DMH)-induced colon carcinomas in rats]
[ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
[Orotate phosphoribosyltransferase levels in gastric carcinoma and normal gastric mucosa - correlation with thymidylate synthase and dihydropyrimidine dehydrogenase levels and the changes after neoadjuvant chemotherapy.]
[Polymorphisms of thymidylate synthase gene and correlation of its protein expression to lymph node metastasis of esophageal squamous cell carcinoma]
[Potentiation of thymidylate synthetase (TS) inhibition by combined administration of HCFU and dipyridamole: preliminary report. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma]
[Thymidylate synthase expression in patients with hypopharyngeal carcinoma]
[Thymidylate synthase inhibition and concentration of 5-fluorouracil after administration of UFT in human uroepithelial carcinomas]
Carcinoma, Adenoid Cystic
Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma.
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in adenoid cystic carcinoma of the head and neck: correlation with clinical outcome.
Carcinoma, Adenosquamous
Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.
Carcinoma, Basal Cell
Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase in squamous cell carcinoma and basal cell carcinoma of the skin.
Carcinoma, Ductal
Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer.
Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives.
Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
Carcinoma, Ehrlich Tumor
Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells.
Purification and characterization of thymidylate synthetase in the liver of the mouse bearing Ehrlich ascites tumor.
Synthetic inhibitors of Escherichia coli, calf thymus, and Ehrlich ascites tumor thymidylate synthetase.
Thymidylate synthetase and thymidine kinase activities and methotrexate cytotoxicity during growth of L1210 and Ehrlich ascites tumor.
Thymidylate synthetase inhibitors. Synthesis of N-substituted 5-aminomethyl-2'-deoxyuridine 5'-phosphates.
Carcinoma, Hepatocellular
A Case-Control Study on the Correlation Between Thymidylate Synthase Gene Polymorphisms and Raltitrexed Treatment Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Treatment.
A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma.
Activities of some enzymes of pyrimidine and DNA synthesis in a rat transplantable hepatoma and human primary hepatomas, in cell lines derived from these tissues, and in human fetal liver.
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Cell cycle patterns of thymidylate synthetase and 5,10-methylenetetrahydrofolate polyglutamates in cultured mouse hepatoma cells.
Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment.
Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.
Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1.
Folate analogues. 32. Synthesis and biological evaluation of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid and related compounds.
Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma.
High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
Increased thymidylate synthase (EC 2.1.1.45) activity in normal and neoplastic proliferation.
Increased thymidylate synthetase in 5-fluorodeoxyuridine resistant cultured hepatoma cells.
Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study.
Inhibition of mammalian thymidylate synthase by 10-formyltetrahydropteroylpolyglutamate.
Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.
Intracellular location of thymidylate synthase and its state of phosphorylation.
Isolation and expression of rat thymidylate synthase cDNA: phylogenetic comparison with human and mouse thymidylate synthases.
Methotrexate decreases thymidine kinase activity.
Modulation of 5-fluorouracil cytotoxicity through thymidylate synthase and NF-kappaB down-regulation and its application on the radiolabelled iododeoxyuridine therapy on human hepatoma cell.
Nucleotide interconversions. IV. Activities of deoxycytidylate deaminase and thymidylate synthetase in normal rat liver and hepatomas.
Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model.
Regulation of de novo and salvage pathways in chemotherapy.
Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma.
Simple separation of tritiated water and [3H]deoxyuridine from [5-3H]deoxyuridine 5'-monophosphate in the thymidylate synthase assay.
Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
Synthesis and biological activity of N(alpha)-[4-[N-[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-N-propargylamino]phenylacetyl]-L-glutamic acid.
The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.
Thymidylate synthase gene polymorphisms as important contributors affecting hepatocellular carcinoma prognosis.
[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis]
Carcinoma, Neuroendocrine
High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes.
[Basic and translational research progress of gastrointestinal neuroendocrine neoplasmas].
Carcinoma, Non-Small-Cell Lung
Antimetabolites and cancer: emerging data with a focus on antifolates.
Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.
Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Association between TYMS Expression and Efficacy of Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.
Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression.
Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.
Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer.
Correlation of Expression Levels of Copper Transporter 1 and Thymidylate Synthase with Treatment Outcomes in Patients with Advanced Non-small Cell Lung Cancer Treated with S-1/Carboplatin Doublet Chemotherapy
Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach.
Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer.
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung.
Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma.
Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
Early detection of thymidylate synthase resistance in non-small cell lung cancer with FLT-PET imaging.
Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients.
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Expression of thymidylate synthase in human non-small cell lung cancer.
Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC).
High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes.
Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase-Targeted Therapies in Non-Small Cell Lung Cancer.
Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
Pemetrexed disodium (Eli Lilly).
Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹?F]fluorothymidine positron emission tomography.
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy.
Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer.
Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: a systematic review and meta-analysis.
Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer.
Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients.
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer.
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy.
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.
The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil.
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.
Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
Thymidylate synthase expression in high-grade neuroendocrine and non-small cell lung cancer histotypes--is it ready for primetime?
Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma.
Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
Thymidylate synthase inhibitors for non-small cell lung cancer.
Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.
Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.
Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.
Up-regulation of ERK1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small cell lung cancer cells.
[Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].
Carcinoma, Ovarian Epithelial
Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma.
Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy.
Relationship between the expression of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase and survival in epithelial ovarian cancer.
Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis.
Carcinoma, Pancreatic Ductal
Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives.
Carcinoma, Renal Cell
Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome.
Significance of thymidine kinase activity in renal cell carcinoma.
Significance of thymidylate synthase activity in renal cell carcinoma.
The combined-action of ici-d1694, 5-fluoro-2'-deoxyuridine and 5-Fluorouracil in inhibiting the growth of a human renal-cell carcinoma cell-line (rpmi-se) in-vitro.
Thymidylate synthetase allelic imbalance in clear cell renal carcinoma.
Carcinoma, Squamous Cell
A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma.
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma.
Characterization of the effect of AG337, a novel lipophilic thymidylate synthase inhibitor, on human head and neck and human leukemia cell lines.
Clinical relevance of thymidylate synthase (TS) activity for S-1-based chemotherapy in squamous cell carcinoma of the oral cavity.
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinoma.
Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung.
Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study.
Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells.
Intratumoural expression of thymidylate synthase is an independent predictor of prognosis in patients with squamous cell carcinoma of the tongue: results from a retrospective study.
Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer.
Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase in squamous cell carcinoma and basal cell carcinoma of the skin.
Relative level of thymidylate synthase mRNA expression in primary tumors and normal tissues predicts survival of patients with oral tongue squamous cell carcinoma.
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck.
Thymidylate synthase 5'- and 3'-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck.
Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.
Thymidylate synthase expression as a predictor of clinical response to 5-fluorouracil-based chemoradiotherapy in patients with maxillary sinus squamous cell carcinoma.
Carcinosarcoma
Evaluation of 1-(3,4-dichlorophenyl)-4-dimethylaminomethyl-1-nonen-3-one hydrochloride effect on nucleic acid and protein syntheses using murine leukemia L-1210 cells.
Cardiotoxicity
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants.
Cardiovascular Diseases
A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma.
Chickenpox
Structure of the Varicella Zoster Virus Thymidylate Synthase Establishes Functional and Structural Similarities as the Human Enzyme and Potentiates Itself as a Target of Brivudine.
Cholangiocarcinoma
FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.
Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population.
Retraction Note to: FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.
Role of dihydropyrimidine dehydrogenase and thymidylate synthase expression in immunohistochemistry of intrahepatic cholangiocarcinoma.
Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.
Cholera
Attenuation of bacterial virulence by quorum sensing-regulated lysis.
Choriocarcinoma
Thymidylate synthase mRNA expression does not predict resistance to floxuridine in a choriocarcinoma cell line.
Coccidiosis
Thymidylate synthetase as a chemotherapeutic target in the treatment of avian coccidiosis.
Colonic Neoplasms
A Combined Analysis of Mismatch Repair Status and Thymidylate Synthase Expression in Stage II and III Colon Cancer.
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Accomplishments in 2007 in biologic markers for gastrointestinal cancers.
Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.
Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats.
AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma.
Binding of 5-fluorodeoxyuridylate to thymidylate synthase in human colon adenocarcinoma xenografts.
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells.
Characteristics of thymidylate synthase purified from a human colon adenocarcinoma.
Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase.
Characterization of the pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in xenografts of human colon adenocarcinoma.
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects.
Comparison of 5-fluoro-2'-deoxyuridine and 5-fluorouracil in the treatment of murine colon cancer; effects on thymidylate synthase.
Detection and quantitation of thymidylate synthase mRNA in human colon adenocarcinoma cell line resistant to 5-fluorouracil by competitive PCR.
Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage.
Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells.
Effect of 2'-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells.
Effect of leucovorin on 5-fluorouracil induced inhibition of thymidylate synthase in patients with colon cancer.
Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft.
Effects of 5,8-dideazaisopteroylglutamate and its possible tri-gamma-glutamyl metabolite (5,8-dideazaisoPteGlu3) on colon adenocarcinoma, and the folate dependent enzymes thymidylate synthase and dihydrofolate reductase.
Effects of ligand binding and conformational switching on intracellular stability of human thymidylate synthase.
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) and Microsatellite Instability in Patients with Colorectal Cancer and Its Clinical Features.
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.
Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer.
Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation.
Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer.
Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts.
Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.
Human dihydrofolate reductase and thymidylate synthase form a complex in vitro and co-localize in normal and cancer cells.
Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy.
Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.
Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells.
Identification of in vivo target RNA sequences bound by thymidylate synthase.
Immunoassay for thymidylate synthase in cytosols from human colorectal-carcinoma cell-lines.
Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination.
Improved synthetic routes to 5,8-dideazapteroylglutamates amenable to the formation of poly-gamma-L-glutamyl derivatives.
In vitro and in vivo inhibition of thymidylate synthase of human colon cancer by 5-fluorouracil.
In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells.
Induction of CaSR expression circumvents the molecular features of malignant CaSR null colon cancer cells.
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Logistic regression model of the clinical response to 5-fluorouracil based chemotherapy for metastatic colorectal cancer patients.
Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed.
Molecular Predictors of Lymph Node Metastasis in Colon Cancer: Increased Risk With Decreased Thymidylate Synthase Expression.
Multi-level gene expression profiles affected by thymidylate synthase and 5-FU in colon cancer.
Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency.
Mutation(s) of the thymidylate synthase gene of human adenocarcinoma cells causes a thymidylate synthase-negative phenotype that can be attenuated by exogenous folates.
p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.
Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients.
Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer.
Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer.
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.
Prognostic and predictive value of thymidylate synthase expression in colon cancer.
Prognostic value of thymidylate synthase, epidermal growth factor receptors and vascular endothelial growth factor in patients with stage III colon cancer.
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death.
Regulation of p53 expression by thymidylate synthase.
Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma.
Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas.
Role of biological markers in the clinical outcome of colon cancer.
Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells.
Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system.
The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells.
The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro.
Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer.
Thymidylate synthase expression in stage II and III colon cancer: a retrospective review.
Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.
Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer.
Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer.
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer.
Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.
Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines.
Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
Thymidylate synthase polymorphism in Mexican patients with colon cancer treated with 5-fluorouracil.
Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival.
Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex.
Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations.
Treatment of metastatic colorectal carcinoma. Recent advances in use of fluorouracil.
TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
Uptake and metabolism of 5,8-dideazaisofolic acid in human colon carcinoma cells.
Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy.
[Analysis of the salvage synthesis within biosynthesis of nucleic acid route in colon cancer]
[Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells]
[Dihydropyrimidine dehydrogenase and thymidylate synthase activities in colonic cancer tissue and sensitivity to 5-fluorouracil]
[Significance of thymidylate synthase and dihydropyrimidine dehydrogenase activity in colon cancer]
[The effect of UFT on thymidine kinase and thymidylate synthetase activities and autoradiograph in DMH-induced colon cancer in rat]
[The intratumoral levels of thymidylate synthetase and folate in gastric and colon cancer]
Colorectal Neoplasms
3'-UTR Polymorphisms in Thymidylate Synthase with Colorectal Cancer Prevalence and Prognosis.
3R Variant of Thymidylate Synthase 5'-untranslated Enhanced Region Contributes to Colorectal Cancer Risk: A Meta-analysis.
5' and 3' UTR thymidylate synthase polymorphisms modulate the risk of colorectal cancer independently of the intake of methyl group donors.
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.
A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance.
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
A practical approach for assessing chemosensitivity in colorectal cancer cell lines by comparative analysis of cell viability and thymidylate synthase mRNA expression.
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Activity of thymidylate synthetase, thymidine kinase and galactokinase in primary and xenografted human colorectal cancers in relation to their chromosomal patterns.
Age-dependent effects of floxuridine (FUdR) on senescent pathology and mortality in the nematode Caenorhabditis elegans.
Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients.
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens.
Analysis of the mRNA Expression Levels of Thymidylate Synthase (TS), Dihydropyrimidine Dehydrogenase (DPD) and Orotate Phosphoribosyl Transferase (OPRT) in Liver Metastases from Colorectal Cancer.
Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug response.
Analysis of uracil DNA glycosylase in human colorectal cancer.
AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma.
Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Association between p53 expression and Bcl-2, P-glycoprotein, topoisomerase II alpha, thymidylate synthase and thymidine phosphorylase as potential therapeutic targets in colorectal cancer patients.
Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer.
Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.
Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity.
Bcl-2 expression significantly correlates with thymidylate synthase expression in colorectal cancer patients.
Capecitabine-mediated heart failure in colorectal cancer: a case series.
Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil.
Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications.
Characterization of a polyclonal antibody to human thymidylate synthase suitable for the study of colorectal cancer specimens.
Chemotherapy of colorectal cancer: history and new themes.
Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
Clinical and preclinical pharmacokinetics of raltitrexed.
Clinical colorectal cancer: thymidylate synthase as a molecular biomarker.
Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy.
Clinical relevance of thymidylate synthase expression in the signet ring cell histotype component of colorectal carcinoma.
Clinically relevant drug-drug interactions in oncology.
Colorectal cancer: the challenge.
Colorectal carcinomas with microsatellite instability display increased thymidylate synthase gene expression levels.
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Combination of 5-fluorouracil and N1,N11-diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma cells.
Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.
Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors.
Coptidis Rhizoma Extract Reverses 5-Fluorouracil Resistance in HCT116 Human Colorectal Cancer Cells via Modulation of Thymidylate Synthase.
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.
Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma.
Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
Correlations of Clinicopathological Factors with Protein Expression Levels of Thymidylate Synthase, Dihydropyrimidine Dehydrogenase and Orotate Phosphoribosyltransferase in Colorectal Cancer.
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.
Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information.
Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: impact on adjuvant treatment.
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
Do the expression of CD44, apoptosis and thymidylate synthase inhibition rate correlate with the efficacy of chemotherapy in colorectal cancer?
Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?
Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients.
Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells.
E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.
Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase.
Effects of 5-fluorouracil derivative UFT on thymidylate synthetase and thymidine kinase in rat colorectal tumors.
Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Enhanced DNA-directed effects of FdUMP[10] compared to 5FU.
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Exposure-response analysis of Raltitrexed assessing liver toxicity.
Expression and gene regulation network of TYMS and BCL2L1 in colorectal cancer based on data mining.
Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.
Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
Expression of dihydropyrimidine dehydrogenase, orotate phosphoribosyl transferase and thymidylate synthase in patients with primary colorectal cancer, and associations with site of first metastasis.
Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy.
Expression of ERCC1 and TYMS in colorectal cancer patients and the predictive value of chemotherapy efficacy.
Expression of thymidylate synthase gene in human colorectal carcinomas by northern blotting and reflectance in-situ hybridization (rish) - correlation with the number of chromosome-18.
Expression of thymidylate synthase in liver and lung metastases of colorectal cancer and their matched primary tumours.
Failure of detection of the tyrosine to histidine substitution at the residue 33 of thymidylate synthase in human colorectal cancer. A preliminary study.
Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells.
Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity.
G>C SNP of thymidylate synthase with respect to colorectal cancer.
Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis.
Gene expression of vascular endothelial growth factor a, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Genetic heterogeneity of variable number tandem repeats in thymidylate synthase gene in colorectal cancer patients.
Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.
Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients.
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.
High thymidylate synthase expression is typical for sporadic MSI-H colorectal carcinoma.
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.
HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug.
Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil.
Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination.
Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
Immunohistochemical expression of thymidylate synthase as a prognostic factor and as a chemotherapeutic efficacy index in patients with colorectal carcinoma.
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.
Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties.
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival.
Individualization of therapy for colorectal cancer based on clinical and molecular parameters.
Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer.
Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer.
Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Inhibition of NF-?B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer.
Inhibition of thymidylate synthase: biochemical pharmacology of drugs with activity in colorectal cancer.
Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer.
Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance.
Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients: association with survival.
Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer.
Isolation and characterization of a thymidylate synthase-deficient human colon tumor cell line.
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer.
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies.
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy.
Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.
Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors.
Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells.
Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
Methylenetetrahydrofolate reductase C677T is not associated with expression of pyrimidine metabolic enzyme genes in colorectal cancer.
Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.
MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer.
MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase.
MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.
Microsatellite instability and the association with plasma homocysteine and thymidylate synthase in colorectal cancer.
Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.
miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma.
Molecular basis of antifolate resistance.
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
New agents for colon and breast cancer.
New antimetabolites in cancer chemotherapy and their clinical impact.
New approaches to the treatment of gastro-intestinal cancer.
New promising anticancer agents in development: what comes next?
New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.
Non-covalent interactions involving halogenated derivatives of capecitabine and thymidylate synthase: a computational approach.
Novel approaches in the treatment of non-small-cell lung cancer.
Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer.
Nuclear expression of thymidylate synthase in colorectal cancer cell lines and clinical samples.
Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor.
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck.
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification.
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells.
p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.
p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer.
p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.
Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.
Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer.
Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients.
Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Polymorphisms in the thymidylate synthase gene and risk of colorectal cancer.
Polymorphisms in the thymidylate synthase gene predict response to 5-fluorouracil therapy in colorectal cancer.
Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population.
Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.
Predictive Potential of PD-L1, TYMS, and DCC Expressions in Treatment Outcome of Colorectal Carcinoma.
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies.
Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis.
Prognostic and Predictive role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study.
Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer.
Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer.
Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy.
Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors.
Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer.
Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil.
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
Protective effects of an antiulcer agent, ecabet sodium on colorectal carcinogenesis in rodents.
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial.
Rabdosianone I, a Bitter Diterpene from an Oriental Herb, Suppresses Thymidylate Synthase Expression by Directly Binding to ANT2 and PHB2.
Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer.
Raltitrexed (Tomudex).
Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.
Raltitrexed increases tumorigenesis as a single agent yet exhibits anti-tumor synergy with 5-fluorouracil in ApcMin/+ mice.
Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method.
Relationship between thymidylate synthase (TS) genotype and TS expression: a tissue microarray analysis of colorectal cancers.
Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.
Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate.
Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: Results of a randomised multicentre trial.
Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer.
Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features.
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Significance of Differential Expression of Thymidylate Synthase in Normal and Primary Tumor Tissues from Patients with Colorectal Cancer.
Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
Structural analysis of cDNA encoding thymidylate synthase in hepatic metastases of human colorectal tumors.
Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors.
Studying the predictive/prognostic role of thymidylate synthase genotypes in patients with colorectal cancer: Is one polymorphism enough?
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.
Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase.
Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
The effect of surgically induced ischaemia on gene expression in a colorectal cancer xenograft model.
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer.
The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil.
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell lines.
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer.
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Thymidylate synthase (TS) protein expression as a prognostic factor in advanced colorectal cancer: a comparison with TS mRNA expression.
Thymidylate synthase and cyclin d1 protein expression in lymph node negative colorectal cancer: role as prognostic factors?
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Thymidylate synthase and microsatellite instability in colorectal cancer: Implications for disease free survival, treatment response and survival with metastases.
Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma.
Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.
Thymidylate synthase as a predictor of response.
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil.
Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
Thymidylate synthase expression and prognosis in colorectal cancer: a meta-analysis of colorectal cancer survival data.
Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.
Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer.
Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial.
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients.
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Thymidylate synthase expression in colorectal cancer: the never-ending story.
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer.
Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy.
Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody.
Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases.
Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases.
Thymidylate synthase expression in rectal cancer and proliferation, assessed by cyclin A and Ki-67 expression.
Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
Thymidylate synthase expression pattern is a prognostic factor in patients of colorectal cancer treated with 5-fluorouracil.
Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.
Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer.
Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer.
Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxy-uridine-5'-monophosphate.
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
Thymidylate Synthase Gene Expression in Primary Colorectal Cancer and Metastatic Sites.
Thymidylate Synthase Gene Polymorphism and Survival of Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil.
Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer.
Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.
Thymidylate synthase genetic polymorphisms and colorectal cancer risk: A meta-analysis.
Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines.
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Thymidylate synthase inhibitors in colorectal cancer.
Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer: a preliminary study.
Thymidylate synthase levels in tumor biopsies from patients with colorectal cancer.
Thymidylate synthase pharmacogenetics in colorectal cancer.
Thymidylate Synthase Pharmacogenetics in Colorectal Cancer.
Thymidylate synthase polymorphism and microsatellite instability: association in colorectal cancer.
Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil.
Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Thymidylate Synthase, Thymidine Phosphorylase, VEGF and p53 Protein Expression in Primary Colorectal Cancer for Predicting Response to 5-fluorouracil-based Chemotherapy.
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil.
Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy.
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?
Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas.
TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
TYMS serves as a prognostic indicator to predict the lymph node metastasis in Chinese patients with colorectal cancer.
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
ZD-9331 AstraZeneca.
ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
[A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer]
[Activities of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with colorectal cancer]
[Changes of the number of FdUMP binding sites of thymidylate synthase and folate pools in human colorectal carcinomas following the administration of tegafur and uracil: preliminary report]
[Correlation between 5-fluorouracil (5-FU) sensitivity as measured by collagen gel droplet embedded culture drug sensitivity test (CD-DST) and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer]
[Correlation between clinical pathologic factors and enzymatic activity of orotate Phosphoribosyl transferase (OPRT), Dihydropyrimidine dehydrogenase (DPD) and Thymidylate synthase (TS) in colorectal cancer]
[Correlation between clinical pathophysiologic factors and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer]
[Effects of RNA interference and nolatrexed on thymidylate synthase expression and cell proliferation of human colorectal carcinoma LOVO cells].
[Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment]
[Expression of mRNA levels of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in diffusely infiltrating colorectal cancer]
[Expression of thymidylate synthase gene and recurrence of colorectal carcinoma: their relation and clinical significance]
[Neo-adjuvant chemotherapy with tegafur suppository for rectal cancer--evaluation of the antitumor effects, tissue levels of 5-FU and inhibition of thymidylate synthase. Tochigi Colorectal Cancer Study Group]
[Potentiation of thymidylate synthetase (TS) inhibition by combined administration of HCFU and dipyridamole: preliminary report. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma]
[Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].
[Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment]
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]
[Relationship between expression of thymidylate synthase and colorectal carcinoma]
[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase]
[Some problems of TS measurement after administration of fluoropyrimidines in colorectal cancer. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma]
[The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy].
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
[Thymidylate synthase activity after preoperative administration of 5-FU in patients with gastric or colorectal cancer]
[Thymidylate synthase and dihydropyrimidine dehydrogenase activity in a metastatic liver tumor from colorectal cancer]
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method]
Communicable Diseases
Antifolate agents: a patent review (2010 - 2013).
Site-directed ligand discovery.
Coronary Artery Disease
Interactions of 5'-UTR thymidylate synthase polymorphism with 677C? T methylene tetrahydrofolate reductase and 66A? G methyltetrahydrofolate homocysteine methyl-transferase reductase polymorphisms determine susceptibility to coronary artery disease.
Crohn Disease
A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.
Cytomegalovirus Infections
Human cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent fibroblasts.
dihydrofolate reductase deficiency
Construction of a dihydrofolate reductase-deficient mutant of Escherichia coli by gene replacement.
dihydropyrimidinase deficiency
A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma.
Exposure-response analysis of Raltitrexed assessing liver toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma.
Exposure-response analysis of Raltitrexed assessing liver toxicity.
Drug-Related Side Effects and Adverse Reactions
Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Elephantiasis, Filarial
An insight into the discovery of potent antifilarial leads against lymphatic filariasis.
Endometrial Neoplasms
Association of thymidylate synthase gene with endometrial cancer risk in a Chinese population.
Esophageal Neoplasms
Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.
Is there a correlation between molecular markers and response to neoadjuvant chemoradiotherapy in locally advanced squamous cell esophageal cancer?
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer.
Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer.
Esophageal Squamous Cell Carcinoma
Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma.
Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis.
Expression of thymidylate synthase and glutathione-s-transferase pi in patients with esophageal squamous cell carcinoma.
Genetic polymorphisms in folate- metabolizing enzymes and risk of gastroesophageal cancers: a potential nutrient-gene interaction in cancer development.
Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer.
[ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
[Polymorphisms of thymidylate synthase gene and correlation of its protein expression to lymph node metastasis of esophageal squamous cell carcinoma]
Esophageal Stenosis
A unique case of a patient with rectal cancer who developed benign esophageal stenosis after localized rectal radiation and systemic chemotherapy.
Fibrosarcoma
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. II. Synthesis and antitumor activity of N5-substituted glutamine analogs.
Fowlpox
Establishment and characterization of a thymidine kinase deficient avian fibroblast cell line derived from a Japanese quail cell line, QT35.
Fragile X Syndrome
Thymidylate metabolism in fragile X syndrome cells.
Gallbladder Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer.
Gastrointestinal Neoplasms
Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects.
Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells.
Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa.
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer.
Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
Molecular markers predictive of response to chemotherapy in gastrointestinal tumors.
Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers.
Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer.
Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy.
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review.
Glioblastoma
Auger electron therapy of glioblastoma using [125I]5-iodo-2'-deoxyuridine and concomitant chemotherapy - Evaluation of a potential treatment strategy.
Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Glioma
5-Fluorocytosine-mediated apoptosis and DNA damage in glioma cells engineered to express cytosine deaminase and their enhancement with interferon.
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Expression of TYMS in lymph node metastasis from low-grade glioma.
Graft vs Host Disease
Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.
Head and Neck Neoplasms
A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma.
Etodolac Improves 5-FU Sensitivity of Head and Neck Cancer Cells through Inhibition of Thymidylate Synthase.
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
[Thymidylate synthase gene promoter polymorphism in advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy.]
Hemangiosarcoma
Expression of thymidylate synthase (TS) and its prognostic significance in patients with cutaneous angiosarcoma.
Hematologic Neoplasms
Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis.
Herpes Simplex
Antiviral activity of 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl-5-iodocytosine against human cytomegalovirus in human skin fibroblasts.
Effects of ribonucleotide reductase inhibition on pyrimidine deoxynucleotide metabolism in acyclovir-treated cells infected with herpes simplex virus type 1.
Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer.
Establishment of mutant FM3A murine mammary carcinoma cell strains transformed with the herpes simplex virus type 1 thymidine kinase gene.
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
Potent activity of 5-fluoro-2'-deoxyuridine and related compounds against thymidine kinase-deficient (TK-) herpes simplex virus: targeted at thymidylate synthase.
Roles of thymidylate synthetase activity in herpes simplex virus-infected HeLa cells.
The A+T-rich genome of Herpesvirus saimiri contains a highly conserved gene for thymidylate synthase.
The cytostatic activity of 5-(1-azidovinyl)-2'-deoxyuridine (AzVDU) against herpes simplex virus thymidine kinase gene-transfected FM3A cells is due to inhibition of thymidylate synthase and enhanced by UV light (lambda = 254 nm) exposure.
Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Herpes Zoster
Structure of the Varicella Zoster Virus Thymidylate Synthase Establishes Functional and Structural Similarities as the Human Enzyme and Potentiates Itself as a Target of Brivudine.
Hyperthyroidism
Effect of altered thyroid status on lysosomal enzymes and thymidylate synthetase activity in tumors and livers of host animals.
Hypothyroidism
Correlation of DNA accumulation rate with thymidylate synthetase activity in developing rat cerebellum: effect of hypothyroidism.
Effect of altered thyroid status on lysosomal enzymes and thymidylate synthetase activity in tumors and livers of host animals.
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri.
Infections
Acquisition of thymidylate synthetase activity by a thymine-requiring mutant of Bacillus subtilis following infection by the temperate phage phi 3.
Bacteriophage phi W-14-infected Pseudomonas acidovorans synthesizes hydroxymethyldeoxyuridine triphosphate.
Effects of ribonucleotide reductase inhibition on pyrimidine deoxynucleotide metabolism in acyclovir-treated cells infected with herpes simplex virus type 1.
Human cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent fibroblasts.
Human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) is part of reverse transcription complexes and acts as an accessory factor for reverse transcription.
Identification of microRNAs with heat stress responsive and immune properties in Marsupenaeus japonicus based on next-generation sequencing and bioinformatics analysis: Essential regulators in the heat stress-host interactions.
Inactivation of the Thymidylate Synthase thyA in Non-typeable Haemophilus influenzae Modulates Antibiotic Resistance and Has a Strong Impact on Its Interplay with the Host Airways.
Murine cytomegalovirus stimulates cellular thymidylate synthase gene expression in quiescent cells and requires the enzyme for replication.
Replication of thymidine kinase deficient herpes simplex virus type 1 in neuronal cell culture: infection of the PC 12 cell.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
The crystal structure of thymidylate synthase from Pneumocystis carinii reveals a fungal insert important for drug design.
Transcriptomic and Metabolomics Profiling of Phage-Host Interactions between Phage PaP1 and Pseudomonas aeruginosa.
Ischemic Stroke
The 3'-UTR Polymorphisms in the Thymidylate Synthase (TS) Gene Associated with the Risk of Ischemic Stroke and Silent Brain Infarction.
Leiomyoma
PTEN, tau-AP-3, thymidylate synthase immunohistochemistry scoring expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignancy potential and uterine leiomyosarcomas.
Leiomyosarcoma
PTEN, tau-AP-3, thymidylate synthase immunohistochemistry scoring expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignancy potential and uterine leiomyosarcomas.
Leishmaniasis
Probing the structure of Leishmania major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads.
Leukemia
123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines.
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Acyclic analogues of 5-fluoro-dUMP and 5-fluoro-2'-deoxyuridine: synthesis and inhibition of thymidylate synthase and tumour cell growth.
Amplification of the thymidylate synthase gene in an N10-propargyl-5,8-dideazafolic-acid-resistant human leukemia, MOLT-3 cell line developed in pteroylglutamic acid, but not in leucovorin.
Association of Thymidylate Synthase 5'-UTR 28bp Tandem Repeat and Serine Hydroxymethyltransfarase C1420T Polymorphisms with Susceptibility to Acute Leukemia.
beta-Carboline-benzoquinolizidine alkaloid deoxytubulosine inhibits thymidylate synthase activity in leukemic leukocytes from patients with chronic myeloblastic leukemia and acute lymphoblastic leukemia.
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.
Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Characterization of the effect of AG337, a novel lipophilic thymidylate synthase inhibitor, on human head and neck and human leukemia cell lines.
Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake.
Comparison of the biological effects of selected 5,8-dideazafolate analogues with their 2-desamino counterparts.
Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinoma.
Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells.
Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
Effects of methotrexate on folates in Krebs ascites and L1210 murine leukemia cells.
Effects of UFT (mixed compound of tegafur and uracil) on cell kinetics and inhibition of thymidylate synthase in L1210 ascites tumor.
Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line.
Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.
Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
Inhibition of murine thymidylate synthase and human dihydrofolate reductase by 5,8-dideaza analogues of folic acid and aminopterin.
Inhibitory action of 10-deazaaminopterins and their polyglutamates on human thymidylate synthase.
Interconversion of tetrahydrofolate cofactors to dihydrofolate induced by trimetrexate after suppression of thymidylate synthase by fluorodeoxyuridine in L1210 leukemia cells.
Levels of thymidylate synthetase during normal culture growth of L1210 cells.
Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.
Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor.
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL).
N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
Polymorphisms involved in folate metabolism pathways and the risk of the development of childhood acute leukemia.
Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase, dietary folate intake, and the risk of leukemia in adults.
Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia?
Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro.
Rate and extent of interconversion of tetrahydrofolate cofactors to dihydrofolate after cessation of dihydrofolate reductase activity in stationary versus log phase L1210 leukemia cells.
Regulation of thymidylate synthetase in mouse leukemia cells (L1210).
Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Studies with tetrahydrohomofolate and thymidylate synthetase from amethopterin-resistant mouse leukemia cells.
Synergistic effect of 5-fluorodeoxyuridine and quinazoline antifolates on murine leukemia self-cultured in vitro.
The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia.
Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
Thymidylate synthase in childhood acute non-lymphoblastic leukemia.
Thymidylate synthase inhibition in cells with arrested DNA synthesis is not due to an allosteric interaction in the replitase complex.
Thymidylate synthetase and serine transhydroxymethylase activities in preleukemic disorders of erythropoiesis and acute leukemia.
Thymidylate synthetase of in vitro chemically and virally transformed rat cells.
[Polymorphisms of thymidylate synthase gene detected by RT-PCR-denaturing gradient gel electrophoresis in children with acute leukemia.]
Leukemia L1210
10-Propargylaminopterin and alkyl homologues of methotrexate as inhibitors of folate metabolism.
Acyclic analogues of 5-fluoro-dUMP and 5-fluoro-2'-deoxyuridine: synthesis and inhibition of thymidylate synthase and tumour cell growth.
Altered mouse leukemia L1210 thymidylate synthase, associated with cell resistance to 5-fluoro-dUrd, is not mutated but rather reflects posttranslational modification.
Folate analogues. 30. Synthesis and biological evaluation of N10-propargyl-5,8-dideaza-5,6,7,8-tetrahydrofolic acid and related compounds.
Levels of thymidylate synthetase during normal culture growth of L1210 cells.
Linear free energy relationship studies of enzyme active site binding: thymidylate synthase.
Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro.
Strategies for the measurement of the inhibitory effects of thymidine analogs on the activity of thymidylate synthase in intact murine leukemia L1210 cells.
Synthesis and biological activity of N(alpha)-[4-[N-[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-N-propargylamino]phenylacetyl]-L-glutamic acid.
Synthesis and biological activity of novel folic acid analogues: pteroyl-S-alkylhomocysteine sulfoximines.
Synthesis of 5-selenium-substituted uracil derivatives. Inhibition of thymidylate synthetase by 5-hydroseleno-2'-deoxyuridylate.
Thymidylate synthetase as target enzyme for the inhibitory activity of 5-substituted 2'-deoxyuridines on mouse leukemia L1210 cell growth.
Leukemia, Lymphoid
Antitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells.
Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.
Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Binding of N5,N10-methylene tetrahydrofolate and the inhibition of thymidylate synthesis by a folate-binding protein.
Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.
Thymidylate synthase activity in leukocytes from patients with chronic myelocytic leukemia and acute lymphocytic leukemia and its inhibition by phenanthroindolizidine alkaloids pergularinine and tylophorinidine.
Leukemia, Myeloid
Human thymidylate synthetase derived from blast cells of patients with acture myelocytic leukemia. Purification and chracterization.
Leukemia, Myeloid, Acute
Human thymidylate synthetase derived from blast cells of patients with acture myelocytic leukemia. Purification and chracterization.
Inhibitory action of 10-deazaaminopterins and their polyglutamates on human thymidylate synthase.
Mechanisms of resistance to methotrexate in childhood acute lymphoblastic leukemia: circumvention of thymidylate synthase inhibition.
Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL).
Thymidylate synthase in childhood acute non-lymphoblastic leukemia.
Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.
Leukemia, Promyelocytic, Acute
Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Leukemia, T-Cell
Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone.
Leukopenia
Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival.
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Lipodystrophy
Association of thymidylate synthase gene polymorphisms with Stavudine triphosphate intracellular levels and lipodystrophy.
Association of Thymidylate Synthase Polymorphisms with Acute Pancreatitis and/or Peripheral Neuropathy in HIV-Infected Patients on Stavudine-Based Therapy.
Liposarcoma
Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence.
Liver Neoplasms
Folate metabolism-related gene polymorphisms and susceptibility to primary liver cancer in North China.
[Clinical significance of epidermal growth factor receptor and thymidylate synthase expression in primary liver cancer].
[Pharmacokinetic study of tegafur in the hepatic tissue obtained from the patients with liver cancer]
Liver Neoplasms, Experimental
Increased thymidylate synthetase activity in 5-fluorodeoxyuridine-resistant Novikoff hepatoma cells.
Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells.
Thymidylate synthetase activity in the Novikoff hepatoma.
Lung Neoplasms
Antimetabolites and cancer: emerging data with a focus on antifolates.
Assessment of thymidylate synthase expression in biopsy specimens and corresponding resection specimens of non-small-cell lung cancer.
Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.
Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Association between TYMS Expression and Efficacy of Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.
Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression.
Biochemical and pharmacologic rationale for high-dose methotrexate.
Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer.
Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.
Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer.
Correlation of Expression Levels of Copper Transporter 1 and Thymidylate Synthase with Treatment Outcomes in Patients with Advanced Non-small Cell Lung Cancer Treated with S-1/Carboplatin Doublet Chemotherapy
Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach.
Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed.
Detection of resistance proteins in matched primary lung tumors and lymph node metastases.
Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer.
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung.
Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma.
E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.
Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
Early detection of thymidylate synthase resistance in non-small cell lung cancer with FLT-PET imaging.
Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients.
Effects of the combination of acivicin and cis-diamminedichloroplatinum(II) on thymidylate synthesis of A549 lung cancer cells.
Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Expression of thymidylate synthase in human non-small cell lung cancer.
Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC).
Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.
Expression of thymidylate synthase predicts clinical outcomes of S-1-based chemotherapy in squamous cell lung cancer.
FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells.
Higher Tissue Levels of Thymidylate Synthase Determined by ELISA Are Associated with Poor Prognosis of Patients with Lung Cancer.
Histologic subtype in NSCLC: does it matter?
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21 expression.
Identification of thymidylate synthase as a potential therapeutic target for lung cancer.
IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells.
Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study.
Impact of thymidylate synthase protein expression on efficacy of chemotherapy in advanced lung cancer patients.
Improved assay method of dTMP synthase in rat liver and its application to human lung cancer cells.
In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer.
Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Influence of polymorphisms in MTHFR 677 C?T, TYMS 3R?2R and MTR 2756 A?G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.
Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase-Targeted Therapies in Non-Small Cell Lung Cancer.
Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.
Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction.
Nitroglycerin Enhances Cisplatin-Induced Cytotoxicity via AKT Inactivation and Thymidylate Synthase Downregulation in Human Lung Cancer Cells.
Pemetrexed disodium (Eli Lilly).
Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹?F]fluorothymidine positron emission tomography.
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.
Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
Polymorphism rs3819102 in thymidylate synthase and environmental factors: effects on lung cancer in Chinese population.
Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy.
Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer.
Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open.
Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: a systematic review and meta-analysis.
Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer.
Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer.
Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients.
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer.
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells.
Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression.
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy.
Significance of thymidylate synthase for resistance to pemetrexed in lung cancer.
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.
The influence of methylenetetrahydrofolate reductase and thymidylate synthetase gene polymorphisms on lung adenocarcinoma occurrence.
The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.
The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III ?-tubulin, and the therapeutic effect of S-1 or carboplatin plus paclitaxel in non-small-cell lung cancer.
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population.
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil.
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.
Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.
Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
Thymidylate synthase expression in high-grade neuroendocrine and non-small cell lung cancer histotypes--is it ready for primetime?
Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma.
Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.
Thymidylate synthase inhibitors for non-small cell lung cancer.
Thymidylate Synthase Polymorphisms and Risk of Lung Cancer among the Jordanian Population: a Case Control Study.
Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.
Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.
Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.
Thymidylate Synthase, Dihydropyrimidine Dehydrogenase, Thymidine Phosphorylase, Orotate Phosphoribosyltransferase mRNA Expression in Lung Cancer Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration - A Pilot Study.
Up-regulation of ERK1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small cell lung cancer cells.
Updated clinical information on multitargeted antifolates in lung cancer.
[Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].
Lyme Disease
Function and evolution of plasmid-borne genes for pyrimidine biosynthesis in Borrelia spp.
Lymphatic Metastasis
Detection of resistance proteins in matched primary lung tumors and lymph node metastases.
Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information.
Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Expression of TYMS in lymph node metastasis from low-grade glioma.
Molecular Predictors of Lymph Node Metastasis in Colon Cancer: Increased Risk With Decreased Thymidylate Synthase Expression.
Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis.
TYMS serves as a prognostic indicator to predict the lymph node metastasis in Chinese patients with colorectal cancer.
[Association of thymidylate synthase polymorphism with esophageal squamous-cell carcinoma]
[Expression of some biomarkers in primary colon adenocarcinomas and their lymph node metastases].
[Polymorphisms of thymidylate synthase gene and correlation of its protein expression to lymph node metastasis of esophageal squamous cell carcinoma]
Lymphoma
5,10-Methylenetetrahydro-5-deazafolic acid and analogues: synthesis and biological activities.
Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.
Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma.
Human herpesvirus 8 gene encodes a functional thymidylate synthase.
Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.
The potentiation of radiation response in human colon carcinoma cells in vitro and murine lymphoma in vivo by AG337 (Thymitaq), a novel thymidylate synthase inhibitor.
Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors.
Lymphoma, B-Cell
Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.
Lymphoma, Non-Hodgkin
Purification of thymidylate synthetase from enzyme-poor sources by affinity chromatography.
The association between polymorphic sites in the thymidylate synthase (TYMS) gene and risk of non-Hodgkin lymphoma: a systematic review and pooled analysis.
Malaria
Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine.
Dihydrofolate reductase: thymidylate synthase, a bifunctional polypeptide from Crithidia fasciculata.
Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.
Functional expression of the dihydrofolate reductase and thymidylate synthetase activities of the human malaria parasite Plasmodium falciparum in Escherichia coli.
High-performance liquid chromatographic assay for thymidylate synthase from the human malaria parasite, Plasmodium falciparum.
Loop-Mediated Isothermal Amplification and LFD Combination for Detection of Plasmodium falciparum and Plasmodium vivax.
Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum.
Resistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge cost of fitness.
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors.
The interaction of 5-fluoroorotic acid with transition metals: synthesis and characterisation of Ni(II), Cu(II) and Zn(II) complexes.
Mastocytoma
Inhibition of thymidylate synthase by hydroxyurea in rapidly proliferating P815 mastocytoma cells.
Medulloblastoma
Rethinking medulloblastoma from a targeted therapeutics perspective.
Melanoma
Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid.
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.
Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinoma.
Dual addressing of thymidine synthesis pathways for effective targeting of proliferating melanoma.
Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro.
Increased thymidylate synthase gene expression in metastatic melanoma.
Mechanism(s) regulating inhibition of thymidylate synthase and growth by gamma-L-glutaminyl-4-hydroxy-3-iodobenzene, a novel melanin precursor, in melanogenic melanoma cells.
New thymidylate synthase inhibitors induce apoptosis in melanoma cell lines.
Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma.
Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion.
The properdin-like type I repeats of human thrombospondin contain a cell attachment site.
Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol.
Meningioma
Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.
Mental Retardation, X-Linked
Assignment of human gene encoding thymidylate synthase to chromosome 18 using interspecific cell hybrids between thymidylate synthase-negative mouse mutant cells and human diploid fibroblasts.
Mesothelioma
An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers.
Antimetabolites and cancer: emerging data with a focus on antifolates.
Biomarkers and prognostic factors for malignant pleural mesothelioma.
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Pemetrexed disodium (Eli Lilly).
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from Malignant Pleural Mesothelioma.
Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools.
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.
THYMIDYLATE SYNTHASE AND EXCISION REPAIR-CROSS-COMPLEMENTING GROUP-1 AS PREDICTORS OF RESPONSIVENESS IN MESOTHELIOMA PATIENTS TREATED WITH PEMETREXED-CARBOPLATIN.
Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma.
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Mesothelioma, Malignant
An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers.
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma.
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from Malignant Pleural Mesothelioma.
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.
Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma.
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Migraine Disorders
Thymidylate synthase promoter tandem repeat and MTHFD1 R653Q polymorphisms modulate the risk for migraine conferred by the MTHFR T677 allele.
Mouth Neoplasms
Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation.
[Immunohistochemical and clinicopathological study of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase expression in oral cancer patients responding to UFT]
Mucositis
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Multiple Myeloma
Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk.
Myasthenia Gravis
The thymidylate synthase enhancer region (TSER) polymorphism increases the risk of thymic lymphoid hyperplasia in patients with Myasthenia Gravis.
Nasopharyngeal Carcinoma
Matrix metalloproteinase 1 promotes tumorigenesis and inhibits the sensitivity to 5-fluorouracil of nasopharyngeal carcinoma.
Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma.
Nasopharyngeal Neoplasms
High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
Neoplasm Metastasis
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
Analysis of the mRNA Expression Levels of Thymidylate Synthase (TS), Dihydropyrimidine Dehydrogenase (DPD) and Orotate Phosphoribosyl Transferase (OPRT) in Liver Metastases from Colorectal Cancer.
Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases.
Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine.
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.
Detection of resistance proteins in matched primary lung tumors and lymph node metastases.
Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information.
Do the expression of CD44, apoptosis and thymidylate synthase inhibition rate correlate with the efficacy of chemotherapy in colorectal cancer?
Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Expression of dihydropyrimidine dehydrogenase, orotate phosphoribosyl transferase and thymidylate synthase in patients with primary colorectal cancer, and associations with site of first metastasis.
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82.
Expression of thymidylate synthase in liver and lung metastases of colorectal cancer and their matched primary tumours.
Expression of TYMS in lymph node metastasis from low-grade glioma.
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival.
Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer?
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
Molecular Predictors of Lymph Node Metastasis in Colon Cancer: Increased Risk With Decreased Thymidylate Synthase Expression.
Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy.
p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer.
Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer.
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.
Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis.
Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer.
Proteomics of Sentinel Lymph Nodes in Early Breast Cancer for Identification of Thymidylate Synthase as a Potential Biomarker to Flag Metastasis: A Preliminary Study.
Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases.
Structural analysis of cDNA encoding thymidylate synthase in hepatic metastases of human colorectal tumors.
Thymidylate synthase and microsatellite instability in colorectal cancer: Implications for disease free survival, treatment response and survival with metastases.
Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.
Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases.
Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases.
Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer.
Thymidylate synthase in nodal metastases: prognostic for chemosensitivity but not for adjuvant therapy?
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment.
Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy.
TYMS serves as a prognostic indicator to predict the lymph node metastasis in Chinese patients with colorectal cancer.
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]
[Expression of some biomarkers in primary colon adenocarcinomas and their lymph node metastases].
[Polymorphisms of thymidylate synthase gene and correlation of its protein expression to lymph node metastasis of esophageal squamous cell carcinoma]
[Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].
[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase]
Neoplasm, Residual
Pharmacogenetic Study in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy: Polymorphisms in Thymidylate Synthase, Epidermal Growth Factor Receptor, GSTP1, and DNA Repair Genes.
Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.
Neoplasms
1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents.
1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats.
18F-FLT and 125I-IdUrd uptake increase in human tumour cell lines induced by the thymidylate synthase inhibitor FdUrd.
19F nuclear magnetic resonance imaging of drug distribution in vivo: the disposition of an antifolate anticancer drug in mice.
2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
3'-Deoxy-3'-[
3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging of thymidine kinase 1 activity after 5-fluorouracil treatment in a mouse tumor model.
5-fluoro-2'-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells.
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.
5-Fluorouracil targets thymidylate synthase in the selective suppression of TH17 cell differentiation.
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
5-fluorouracil-mediated thymidylate synthase induction in malignant and nonmalignant human cells.
5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates.
5-fluorouracil: a pharmacological paradigm in the use of cytotoxics.
5-Substituted 2'-deoxyuridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase.
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors.
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
A fast chemoenzymatic synthesis of [(11)C]-N(5),N(10)-methylenetetrahydrofolate as a potential PET tracer for proliferating cells.
A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy.
A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2'-deoxyuridine in mammalian and bacterial cells.
A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line.
A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance.
A new quantitative RT-PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls.
A novel approach to thymidylate synthase as a target for cancer chemotherapy.
A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies.
A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
A possible link to uracil DNA glycosylase in the synergistic action of HDAC inhibitors and thymidylate synthase inhibitors.
A potent multisubstrate analogue inhibitor of human thymidylate synthetase.
A potential important role for thymidylate synthetase inhibition on antitumor activity of fluoropyrimidine and raltitexed.
A Proposed Clinical Test for Monitoring Fluoropyrimidine Therapy: Detection and Stability of Thymidylate Synthase Ternary Complexes.
A Prospective Pilot Study of Target-guided Personalized Chemotherapy with Intensity-modulated Radiotherapy in Patients With Early Rectal Cancer.
A qualitative approach to enzyme inhibition.
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Accomplishments in 2007 in biologic markers for gastrointestinal cancers.
Activity of the cytosolic isozyme of thymidine kinase in human primary lung tumors with reference to malignancy.
Acyclic analogues of 5-fluoro-dUMP and 5-fluoro-2'-deoxyuridine: synthesis and inhibition of thymidylate synthase and tumour cell growth.
Additional effects of medroxyprogesterone acetate on mammary tumors in oophorectomized, estrogenized, DMBA-treated rats.
Additive effects of medroxyprogesterone acetate and 5-fluorouracil derivative on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil.
Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients.
An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers.
Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Antifolate agents: a patent review (2010 - 2013).
Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs.
Antimetabolites and cancer: emerging data with a focus on antifolates.
Antimetabolites.
Antisense nucleic acids targeted to the thymidylate synthase (TS) mRNA translation start site stimulate TS gene transcription.
Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs.
Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition.
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice.
Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.
Antitumour effects of pure diastereoisomers of 5-formyltetrahydrofolate in hepatic transplants of a rodent colon carcinoma model.
AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells.
Assessment of thymidylate synthase expression in biopsy specimens and corresponding resection specimens of non-small-cell lung cancer.
Association Between Genetic Polymorphisms In TYMS And Glioma Risk In Chinese Patients: A Case-Control Study.
Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil.
Association of methylenetetrahydrofolate reductase and thymidylate synthase promoter polymorphisms with genetic susceptibility to esophageal and cardia cancer in a Chinese high-risk population.
Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma.
Association of thymidylate synthase and hypoxia inducible factor-1alpha DNA polymorphisms with pancreatic cancer.
Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
beta-Carboline-benzoquinolizidine alkaloid deoxytubulosine inhibits thymidylate synthase activity in leukemic leukocytes from patients with chronic myeloblastic leukemia and acute lymphoblastic leukemia.
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells.
Biochemical and pharmacologic rationale for high-dose methotrexate.
Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthetase.
Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.
Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer.
Biochemical modulation of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.
Biochemical modulation of 5-fluorouracil with a streptococcal preparation, OK-432, against murine colon-26 carcinoma.
Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
Biochemical modulation of 5-fluorouracil with murine interferon-alpha/beta against murine renal cell carcinoma.
Biochemical modulation of iododeoxyuridine by N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2,6-diaminobenz[cd]indole glucuronate (AG-331) leading to enhanced cytotoxicity.
Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination.
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy.
Biomolecular study of human thymidylate synthase conformer-selective inhibitors: New chemotherapeutic approach.
Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Cell death in response to antimetabolites directed at thymidylate synthase.
Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.
Cellular heterogeneity in DNA damage and growth inhibition induced by ICI D1694, thymidylate synthase inhibitor, using single cell assays.
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
Characterization of the pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in xenografts of human colon adenocarcinoma.
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
Chemosensitivity testing--present and future in Japan.
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index.
Clinical application of biological markers for treatments of resectable non-small-cell lung cancers.
Clinical evaluation of postoperative chemotherapy based on genetic testing in patients with stage IIIA non-small cell lung cancer.
Clinical experience with pemetrexed in breast cancer.
Clinical Experience With Pemetrexed in Breast Cancer.
Clinical implications of 5-FU modulation.
Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules.
CoFactor (Biokeys Pharmaceuticals).
Colorectal carcinomas with microsatellite instability display increased thymidylate synthase gene expression levels.
Column-switching high-performance liquid chromatographic method for the determination of a thymidylate synthase inhibitor, LY231514, an investigational agent for the treatment of solid tumors, in human plasma.
Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts.
Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo.
Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines.
Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects.
Combining Small Interfering RNAs Targeting Thymidylate Synthase and Thymidine Kinase 1 or 2 Sensitizes Human Tumor Cells to 5-Fluorodeoxyuridine and Pemetrexed.
Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.
Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells.
Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Comparing cell kinetic studies of the effect of ftorafur and 5-fluorouracil on the L 1210 ascites tumor.
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.
Constitutive expression of thymidylate synthase from LCDV-C induces a transformed phenotype in fish cells.
Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells.
Contributions of protein structure-based drug design to cancer chemotherapy.
Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones?
Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors.
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.
Correction for Cardinale et al. , Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase.
Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma.
Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
Correlation of Expression Levels of Copper Transporter 1 and Thymidylate Synthase with Treatment Outcomes in Patients with Advanced Non-small Cell Lung Cancer Treated with S-1/Carboplatin Doublet Chemotherapy
Correlation of spectral imaging and visual grading for the quantification of thymidylate synthase protein expression in rectal cancer.
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Correlations of Clinicopathological Factors with Protein Expression Levels of Thymidylate Synthase, Dihydropyrimidine Dehydrogenase and Orotate Phosphoribosyltransferase in Colorectal Cancer.
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth.
Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Cytotoxic response of 5-fluorouracil-resistant cells to gene- and cell-directed enzyme/prodrug treatment.
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
Design, synthesis and in vitro antiproliferative activity of new thiazolidinedione-1,3,4-oxadiazole hybrids as thymidylate synthase inhibitors.
Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations.
Detection of resistance proteins in matched primary lung tumors and lymph node metastases.
Detection of thymidylate synthase modulators by a novel screening assay.
Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.
Determination of thymidylate synthase activity in colon tumor tissues after treatment with 5-fluorouracil.
Development and Binding Mode Assessment of N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-?-glutamyl-d-glutamic Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells.
Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLC.
Development of an assay for the estimation of N10-propargyl-5,8-dideazafolic acid polyglutamates in tumor cells.
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes.
Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients.
Difference in thymidylate synthetase activity in involved nodes compared with primary tumor in breast cancer patients.
Different expression of thymidylate synthase in primary tumour and metastatic nodes in breast cancer patients.
Differential effects of two fluorouracil administration regimens for colorectal cancer.
Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil.
Differentially potentiating effects by dipyridamole on cytotoxicity of 5-fluorouracil against three human maxillary cancer cell lines derived from a single tumor.
Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells.
Dihydropyrimidine Dehydrogenase 85T>C Mutation Is Associated With Ocular Toxicity of 5-Fluorouracil: A Case Report.
Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice.
Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.
Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.
Dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in esophageal cancer patients: Correlation with clinicopathological factors and prognosis.
Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.
Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer.
Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity.
Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa.
Dissociation of thymidylate biosynthesis from DNA biosynthesis by 5-fluoro-2'-deoxyuridine and 5,8-dideazaisofolic acid.
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine.
Do the expression of CD44, apoptosis and thymidylate synthase inhibition rate correlate with the efficacy of chemotherapy in colorectal cancer?
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells.
dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA-repair-defective human cancer cells.
Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells.
E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.
Effect of a combined administration of 5-fluorouracil and medroxyprogesterone acetate on pyrimidine nucleoside phosphorylases and thymidylate synthetase in 7,12-dimethylbenz.
Effect of altered thyroid status on lysosomal enzymes and thymidylate synthetase activity in tumors and livers of host animals.
Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors.
Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft.
Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients.
Effects of beta-carotene-rich algae Dunaliella bardawil on the dynamic changes of normal and neoplastic mammary cells and general metabolism in mice.
Effects of Chinese herbal medicines on DNA-synthesizing enzyme activities in mammary tumors of mice.
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Effects of intravesical instillation of 5-fluorouracil and interferon in patients with recurrent superficial urinary bladder carcinoma. A clinical and pharmacodynamic study.
Effects of long-term administration of UFT plus leucovorin on colorectal tumors induced with 1,2-dimethylhydrazine in rats.
Effects of lycopene on spontaneous mammary tumour development in SHN virgin mice.
Effects of Mg2+ and adenine nucleotides on thymidylate synthetase from different mouse tumors.
Effects of preoperative chemotherapy on gastric carcinoma: the relationship between histopathologic response and prognosis.
Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma.
Effects of tamoxifen on mammary tumors and bone in 7,12-dimethylbenz-(a)anthracene-treated rats.
Effects of UFT (mixed compound of tegafur and uracil) on cell kinetics and inhibition of thymidylate synthase in L1210 ascites tumor.
Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts.
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level.
Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1.
Elevated levels of thymidylate synthase linked to neoplastic transformation of mammalian cells.
Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) and Microsatellite Instability in Patients with Colorectal Cancer and Its Clinical Features.
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.
Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors.
Emerging role of thymidylate synthase for the pharmacogenomic selection of patients with thoracic cancer.
Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer.
Enhanced expression of thymidylate synthase mediates resistance of uterine cervical cancer cells to radiation.
Enhancement by thymidine of 5-fluorouracil's inhibition of thymidylate synthetase in human tumors.
Enhancement of 5-Fluorouracil Cytotoxicity by Pyridoxal 5'-Phosphate and Folinic Acid in Tandem.
Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model.
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase.
Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study.
Epitope analysis and utility of monoclonal antibodies to native and recombinant human thymidylate synthase.
ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
Establishment and characterization of novel xenograft models of human biliary tract carcinomas.
Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues.
Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Evaluation of effects of thymidylate synthase and excision repair cross-complementing 1 polymorphisms on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood.
Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer.
Evaluation of Thymidylate Synthase Expression in Prostate Cancer.
Evaluation of thymidylate synthase protein expression by Western blotting and immunohistochemistry on human colon carcinoma xenografts in nude mice.
Evaluation of [(18)F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer.
Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer.
Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy.
Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Expression of rTSbeta as a 5-fluorouracil resistance marker in patients with primary breast cancer.
Expression of thymidylate synthase (TS) and its prognostic significance in patients with cutaneous angiosarcoma.
Expression of thymidylate synthase in cancer of the ampulla of Vater.
Expression of thymidylate synthase in human non-small cell lung cancer.
Expression of thymidylate synthase in liver and lung metastases of colorectal cancer and their matched primary tumours.
Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC).
Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.
Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition.
Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
Failure of detection of the tyrosine to histidine substitution at the residue 33 of thymidylate synthase in human colorectal cancer. A preliminary study.
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells.
Fluorescence and computational studies of thymidine phosphorylase affinity toward lipidated 5-FU derivatives.
Fluorodeoxyuridine Modulates Cellular Expression of the DNA Base Excision Repair Enzyme Uracil-DNA Glycosylase.
Folate analogues. 21. Synthesis and antifolate and antitumor activities of N10-(cyanomethyl)-5,8-dideazafolic acid.
Folate pathway genetic polymorphisms and susceptibility of central nervous system tumors in Thai children.
Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action.
Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting.
Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS).
Fuplatin: An Efficient and Low-Toxic Dual-Prodrug.
Future potential of thymidylate synthase inhibitors in cancer therapy.
G>C SNP of thymidylate synthase with respect to colorectal cancer.
Gastric cancer with Virchow's and multiple lung metastases showing a remarkable response to preoperative chemotherapy: report of a case.
Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
Gene dosage and expression, and enzyme activity of thymidine kinase and thymidylate synthase in xenografted colorectal adenocarcinomas.
Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review.
Genetic heterogeneity of variable number tandem repeats in thymidylate synthase gene in colorectal cancer patients.
Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer.
Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
Genotoxicity of pemetrexed in human peripheral blood lymphocytes.
Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts.
Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study.
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients.
High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1.
High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.
High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors.
High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase.
High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes.
High-level QM/MM calculations support the concerted mechanism for Michael addition and covalent complex formation in thymidylate synthase.
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells.
Human dihydrofolate reductase and thymidylate synthase form a complex in vitro and co-localize in normal and cancer cells.
Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug.
Human thymidylate synthase with loop 181-197 stabilized in an inactive conformation: ligand interactions, phosphorylation, and inhibition profiles.
ICI D1694 and idoxuridine: a synergistic antitumor combination.
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Identification of thymidylate synthase as a potential therapeutic target for lung cancer.
Immunohistochemical analysis of thymidylate synthase expression in gastric carcinoma: correlation with clinicopathological parameters and survival.
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer.
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial.
Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Impact of thymidylate synthase protein expression on efficacy of chemotherapy in advanced lung cancer patients.
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas.
In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase.
In vitro selected peptides bind with thymidylate synthase mRNA and inhibit its translation.
In vitro selection of an RNA sequence that interacts with high affinity with thymidylate synthase.
In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin.
In vivo antitumor efficacy of CW252053, a folate-based thymidylate synthase inhibitor.
Increased activities of thymidylate synthetase and thymidine kinase in human thyroid tumors.
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil.
Increased thymidylate synthase gene expression in metastatic melanoma.
Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells.
Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells.
Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer.
Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".
Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction.
Inhibition of mammalian tumour thymidylate synthetase by 2'-deoxyuridine 5'-phosphate analogues.
Inhibition of mammalian tumour thymidylate synthetase by 5-alkylated 2'-deoxyuridine 5'-phosphates.
Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein.
Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells.
Inhibition of thymidylate synthase activity by antisense oligodeoxynucleotide and possible role in thymineless treatment.
Inhibition of thymidylate synthase and cell growth by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine.
Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3,4-dihydroxybenzylamine.
Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage.
Inhibitory effect of lignin-related pine cone extract on cell proliferating enzyme activity of spontaneous mammary tumours in mice.
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase.
Interaction between thymidylate synthase and its cognate mRNA in zebrafish embryos.
Interaction of 5-fluoro-4-thio-2'-deoxyuridine 5'-phosphate with mammalian tumour thymidylate synthase: role of the pyrimidine N(3)-H dissociation.
Interferon alpha-2a shows antitumor activity in combination with 5-fluorouracil against human colon carcinoma xenografts: a study in reference to thymidylate synthetase activity inhibition.
Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
Interleukin-2 as a modulator of 5-fluorouracil in hepatic arterial immunochemotherapy for liver metastases.
Intratumor dihydropyrimidine dehydrogenase mRNA expression levels are decreased in extramammary Paget's disease.
Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer.
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells.
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase.
Kinetic properties of human thymidylate synthase, an anticancer drug target.
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
Leucovorin and folic acid regimens for selective expansion of murine 5,10-methylenetetrahydrofolate pools.
Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies.
Logistic regression model of the clinical response to 5-fluorouracil based chemotherapy for metastatic colorectal cancer patients.
Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.
Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU.
Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur.
Mechanism of action of key enzymes associated with cancer propagation and their inhibition by various chemotherapeutic agents.
Mechanism of cytostatic action of novel 5-(thien-2-yl)- and 5-(furan-2-yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of herpes simplex virus.
Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.
Methotrexate analogues. 29. Effect of gamma-aminobutyric acid spacers between the pteroyl and glutamate moieties on enzyme binding and cell growth inhibition.
Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.
MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells.
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem.
Microsatellite instability and the association with plasma homocysteine and thymidylate synthase in colorectal cancer.
Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.
miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma.
miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.
Modulation by l-leucovorin of 1-hexylcarbamoyl-5-fluorouracil antitumor activity on human gastric and colon carcinomas serially transplanted into nude mice.
Modulation of 5-fluoro-2'-deoxyuridine response by folinic acid in human colonic tumor cell lines: the role of thymidylate synthase.
Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine.
Modulation of [5-125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors.
Molecular and Dynamic Evaluation of Proteins Related to Resistance to Neoadjuvant Treatment with Chemoradiotherapy in Circulating Tumor Cells of Patients with Locally Advanced Rectal Cancer.
Molecular basis of the interaction of novel tributyltin(IV) 2/4-[(E)-2-(aryl)-1-diazenyl]benzoates endowed with an improved cytotoxic profile: synthesis, structure, biological efficacy and QSAR studies.
Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis.
Molecular markers and prediction of response to chemoradiation in rectal cancer.
Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Molecular prognostic markers in resectable colorectal liver metastases: a systematic review.
MTHFR (C677T) polymorphisms and stage III colon cancer: response to therapy.
Multi-level gene expression profiles affected by thymidylate synthase and 5-FU in colon cancer.
Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer.
Multidrug resistance and its reversal.
Multidrug Resistance in Primary Tumors and Metastases in Patients with Esophageal Squamous Cell Carcinoma.
Multiple molecular alterations in mouse lung tumors.
Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.
Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models.
NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint.
New agents for colon and breast cancer.
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
New drugs for patients with pancreatic cancer.
New Insight into the Octamer of TYMS Stabilized by Intermolecular Cys43-Disulfide.
New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.
Nonpolyglutamatable antifolates as inhibitors of thymidylate synthase (TS) and potential antitumour agents.
Novel chemical strategies for thymidylate synthase inhibition.
Novel combinations with oxaliplatin.
Novel thymidylate synthase enhancer region alleles in African populations.
Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor.
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.
Nucleotide biosynthesis arrest by silencing SHMT1 function via vitamin B6-coupled vector and effects on tumor growth inhibition.
ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines.
Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification.
Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer.
Overexpression of thymidylate synthase mediates desensitization for 5-fluorouracil of tumor cells.
Overview: rational basis for development of fluoropyrimidine/5-formyltetrahydrofolate combination chemotherapy.
p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.
p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer.
p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
Parallel reaction pathways and noncovalent intermediates in thymidylate synthase revealed by experimental and computational tools.
Parenteral nutrition decreases hepatic dihydropyrimidine dehydrogenase activity and modulates catabolism of 5-fluorouracil in rats.
Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.
PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.
Pemetrexed disodium (Eli Lilly).
Pemetrexed for diffuse malignant pleural mesothelioma.
Pemetrexed: an active new agent for breast cancer.
pH-Promoted Release of a Novel Anti-Tumour Peptide by "Stealth" Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells.
Pharmacogenomics of thymidylate synthase in cancer treatment.
Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma.
Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.
Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents.
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors.
Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer.
Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer.
Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review.
Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis.
Polymorphisms of Folate Pathway Enzymes (Methylenetetrahydrofolate Reductase and Thymidylate Synthase) and Their Relationship with Thymidylate Synthase Expression in Human Astrocytic Tumors.
Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors.
Positive Cooperativity in Substrate Binding by Human Thymidylate Synthase.
Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent.
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer.
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.
Predictive value of thymidylate synthase expression in gastric cancer: a systematic review with meta-analysis.
Predictors of response and survival for neoadjuvant treated patients with esophageal adenocarcinoma.
Preferential tumor targeting and selective tumor cell cytotoxicity of 5-[131/125I]iodo-4'-thio-2'-deoxyuridine.
Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity-study of 5-fluorouracil.
Principles of self-organization in biological pathways: a hypothesis on the autogenous association of alpha-synuclein.
Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
Prognostic and predictive factors in colorectal cancer.
Prognostic and predictive molecular markers in colorectal carcinoma.
Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study.
Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma.
Prognostic Significance of miR-215 in Colon Cancer.
Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors.
Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma.
Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.
Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil.
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung.
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Proliferation-dependent cytotoxicity of methotrexate in murine L5178Y leukemia.
Protein Expression Profiles Indicative for Drug Resistance of Kidney Carcinoma.
Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase.
PTEN, tau-AP-3, thymidylate synthase immunohistochemistry scoring expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignancy potential and uterine leiomyosarcomas.
Purification and characterization of thymidylate synthetase in the liver of the mouse bearing Ehrlich ascites tumor.
Purification and properties of mouse thymus thymidylate synthase. Comparison of the enzyme from mammalian normal and tumour tissues.
Purification of mammalian tumor (L1210) thymidylate synthetase by affinity chromatography on stable biospecific adsorbent. Stabilization of the enzyme with neutral detergents.
Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts.
Quantitation of thymidylate synthase in human tumors using an ultrasensitive enzyme-linked immunoassay.
Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.
Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation.
Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Rapid detection of thymidylate synthase gene expression levels by semi-quantitative competitive reverse transcriptase polymerase chain reaction followed by quantitative digital image analysis.
Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells.
Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating fluorouridine concentration in tumor tissue.
Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography.
Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas.
Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
Relative activities of thymidylate synthetase and thymidine kinase in human mammary tumours.
Relative activities of thymidylate synthetase and thymidine kinase in rat tissues.
Relative level of thymidylate synthase mRNA expression in primary tumors and normal tissues predicts survival of patients with oral tongue squamous cell carcinoma.
Resistance proteins in human kidney, breast, ovarian and lung-carcinoma - a comparative-analysis.
Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: Results of a randomised multicentre trial.
Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer.
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.
Role of biological markers in the clinical outcome of colon cancer.
Role of dihydropyrimidine dehydrogenase and thymidylate synthase expression in immunohistochemistry of intrahepatic cholangiocarcinoma.
Role of E2F-1 in chemosensitivity.
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer.
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.
Schedule dependent inhibition of thymidylate synthase and tumor growth by 5-fluorouracil in Yoshida sarcoma bearing rats.
Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
Second-look hepatectomy after 5FU arterial infusion in patients with primary unresectable hepatic colorectal metastases.
Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index.
Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo.
Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver.
Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin.
Sequential inhibitory effects of antitumor agents related to levodopa and dopamine upon DNA synthetic enzymes.
Significance of Differential Expression of Thymidylate Synthase in Normal and Primary Tumor Tissues from Patients with Colorectal Cancer.
Significant increase in risk of gastroesophageal cancer is associated with interaction between promoter polymorphisms in thymidylate synthase and serum folate status.
Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase.
siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.
Site-directed ligand discovery.
Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition.
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
Structural analyses of human thymidylate synthase reveal a site that may control conformational switching between active and inactive states.
Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations.
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors.
Structure of human thymidylate synthase under low-salt conditions.
Structures of human thymidylate synthase R163K with dUMP, FdUMP and glutathione show asymmetric ligand binding.
Studies on resistance against 5-fluorouracil. II. Thymidylate synthetase from drug-resistant tumor lines.
Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors.
Suicide prodrugs activated by thymidylate synthase: rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues.
Superior antimetastatic effect of pemetrexed-loaded gelatinase-responsive nanoparticles in a mouse metastasis model.
Suppression by coffee cherry of the growth of spontaneous mammary tumours in SHN mice.
Suppressive effect of TNF-alpha on increased production of FdUMP by IFN-alpha.
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Synthesis and interaction with thymidylate synthase of 5'-dithiophosphate and 5'-fluorothiophosphate of thymidine.
Synthesis of New 1, 3, 4-Oxadiazole-Incorporated 1, 2, 3-Triazole Moieties as Potential Anticancer Agents Targeting Thymidylate Synthase and Their Docking Studies.
Synthetic inhibitors of Escherichia coli, calf thymus, and Ehrlich ascites tumor thymidylate synthetase.
Systematic Review of Candidate Single-nucleotide Polymorphisms as Biomarkers for Responsiveness to Neoadjuvant Chemoradiation for Rectal Cancer.
Tailor-made chemotherapy for non-small cell lung cancer patients.
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer.
Targeting the alpha-folate receptor with cyclopenta[g]quinazoline-based inhibitors of thymidylate synthase.
Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues.
The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo.
The cytotoxicity of 5-fluorouracil is due to its incorporation into RNA not its inhibition of thymidylate synthase as evidenced by the use of a mouse cell mutant deficient in thymidylate synthase.
The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat.
The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells.
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery.
The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells.
The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger.
The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine.
The place of pemetrexed in the management of non-small-cell lung cancer patients.
The potentiation of radiation response in human colon carcinoma cells in vitro and murine lymphoma in vivo by AG337 (Thymitaq), a novel thymidylate synthase inhibitor.
The presence of three repeats in the 5' UTR region of thymidylate synthase (TS) is associated with increased TS mRNA expression in cultured human cancer cell lines in vitro.
The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.
The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population.
The role of interferon-alpha as a modulator of fluorouracil and leucovorin.
The role of p-glycoprotein, glutathione-s-transferase-pi, thymidylate synthase and metallothionein in the expression of differential sensitivities to antitumor agents in human tumor xenografts.
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.
The role of thymidylate synthase in cellular regulation.
The role of thymidylate synthetase inhibitors in bromodeoxyuridine-induced neoplasia in Drosophila.
Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Third International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Cologne, 23-26 September 1998.
Three-dimensional structure of the R115E mutant of T4-bacteriophage 2'-deoxycytidylate deaminase.
Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.
Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs.
Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo.
Thymidylate synthase (TS) mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.
Thymidylate synthase activity as a prognostic factor in ovarian cancer.
Thymidylate synthase activity in leukocytes from patients with chronic myelocytic leukemia and acute lymphocytic leukemia and its inhibition by phenanthroindolizidine alkaloids pergularinine and tylophorinidine.
Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues.
Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil.
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer.
Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma.
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.
Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma.
Thymidylate synthase as a determinant of 5-fluoro-2'-deoxyuridine response in human colonic tumor cell lines.
Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
Thymidylate synthase as a molecular target for drug discovery using the National Cancer Institute's Anticancer Drug Screen.
Thymidylate synthase as a target in cancer chemotherapy.
Thymidylate synthase as an oncogene?
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity.
Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial.
Thymidylate synthase expression at metastatic site might be more correlated with response to anti-thymidylate synthase agent in triple negative breast cancers.
Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells.
Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients.
Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors.
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer.
Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy.
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.
Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.
Thymidylate synthase gene of herpesvirus ateles.
Thymidylate Synthase Gene Polymorphism Affects the Response to Preoperative 5-Fluorouracil Chemoradiation Therapy in Patients With Rectal Cancer.
Thymidylate synthase gene polymorphisms as important contributors affecting hepatocellular carcinoma prognosis.
Thymidylate synthase gene variations: predictive and prognostic markers.
Thymidylate synthase genetic polymorphisms and cancer risk: a meta-analysis of 37 case-control studies.
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.
Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer.
Thymidylate synthase in advanced gastrointestinal and breast cancers.
Thymidylate synthase in normal and cancer tissues.
Thymidylate synthase inhibition as a predictor of tumor sensitivity of fluorinated pyrimidines.
Thymidylate synthase inhibitors for non-small cell lung cancer.
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial-to-mesenchymal transition of cancer cells.
Thymidylate synthase levels in tumor biopsies from patients with colorectal cancer.
Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers.
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival.
Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis.
Thymidylate synthase polymorphisms and hematological cancer risk: evidence needs further clarification.
Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma.
Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex.
Thymidylate Synthase Protein Expression
Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines.
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy.
Thymidylate synthase structure, function and implication in drug discovery.
Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer.
Thymidylate Synthase, a New Myoepithelial Biomarker for Breast Lesions.
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Thymidylate synthase: a critical target for cancer chemotherapy.
Thymidylate synthase: a critical target in cancer therapy?
Thymidylate synthetase - a target enzyme in cancer chemotherapy.
Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations.
Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.
Thymidylate synthetase and thymidine kinase activities and methotrexate cytotoxicity during growth of L1210 and Ehrlich ascites tumor.
Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil.
Thymidylate synthetase inhibitors. Synthesis of N-substituted 5-aminomethyl-2'-deoxyuridine 5'-phosphates.
Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells.
Topoisomerase 2? and thymidylate synthase expression in adrenocortical cancer.
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas.
Translational research with pemetrexed in breast cancer.
Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport.
TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer.
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Tumor cell responses to inhibition of thymidylate synthase.
Tumor dihydropyrimidine dehydrogenase activity in advanced cervical carcinoma.
Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.
Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma.
Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Tyrosine nitration affects thymidylate synthase properties.
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality.
Unresolved issues in the biochemical pharmacology of antifolates.
Up-regulation in dihydropyrimidine dehydrogenase activity by raltitrexed causes antagonism in combination with 5-fluorouracil.
Up-regulation of resistance-related proteins in human lung tumors with poor vascularization.
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Variation in the expression levels of predictive chemotherapy biomarkers in histological subtypes of lung adenocarcinoma: an immunohistochemical study of tissue samples.
Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy.
Where should the specimen be excised for the chemosensitivity of colorectal cancer to 5-fluorouracil?
ZD-9331 AstraZeneca.
ZD9331 in combination with topotecan: phase I and II experience.
ZD9331: discovery to clinical development.
[
[A case of long-term survival after undergoing s-1 based multidisciplinary therapy for liver metastasis of gastric cancer].
[A case of uterine cervical cancer in which UFT was an effective preoperative treatment]
[A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion]
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]
[Antitumor activity and function of S-1, a new oral tegafur-based formulation]
[Changes in folate levels after cisplatin treatment of gastric cancer]
[Comparison between continuous intravenous and oral administration of 5-FU with LV]
[Comparison between leucovorin and cisplatin as a modulator of 5-fluorouracil]
[Dihydropyrimidine dehydrogenase and thymidylate synthase in colon carcinoma]
[DNA biosynthesis in the liver of animals with extrahepatic tumors: the role of thymidylate synthetase]
[Double promoters induct suicide gene target killing of 5-FU drug-fast cancer cells]
[Dual biochemical modulation therapy using 5-FU, leucovorin and cisplatin on human rectal carcinoma xenografts in nude mouse]
[Effect and mechanism of orally administered leucovorin/5-fluorouracil on colon cancer]
[Evaluation of chemosensitivity testing by CD-DST, and TS and DPD activity in cases of colorectal liver]
[Evaluation of combination chemotherapy with 5-FU and CDDP for human gastric carcinoma transplanted into nude mice]
[Expression of metabolic enzymes of fluoropyrimidines in primary colorectal cancer and its clinical significance]
[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]
[Inhibition of thymidylate synthetase and antiproliferative effect by 1-hexylcarbamoyl-5-fluorouracil]
[Level of inhibition of thymidylate synthase activity and 5-fluorouracil in tumor tissues after administration of UFT or tegafur]
[Metastatic colorectal cancer: new therapeutics]
[Molecular cloning and molecular biological studies of human thymidylate synthase gene]
[Molecular markers as basis for chemotherapy?]
[Neo-adjuvant chemotherapy with tegafur suppository for rectal cancer--evaluation of the antitumor effects, tissue levels of 5-FU and inhibition of thymidylate synthase. Tochigi Colorectal Cancer Study Group]
[Pharmacological and biochemical investigation of intracavital fluorinated pyrimidine chemotherapy]
[Phase I study of raltitrexed (ZD-1694)]
[Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].
[Relationship between antitumor activity and the inhibition of thymidylate synthase after oral administration of UFT in nude mice bearing human tumor]
[Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer]
[Studies of the antitumor activity and enzymology of 2'-deoxy-5-fluorouridine (FdUrd) derivatives]
[Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo]
[The association of expression and gene polymorphism of the thymidylate synthase gene with 5-fluoro-5'-deoxyuridine sensitivity in gastric cancer cell lines]
[The correlation between thymidylate synthase expression and cytotoxicity of 5-fluorouracil in human cancer cell lines: study using polyclonal antibody against recombinant human thymidylate synthase]
[The determination of thymidylate synthetase inhibition for testing fluoropyrimidines--pharmacokinetics and metabolism of carmofur (HCFU) in patients with gynecologic malignancies--Tokai HCFU Study Group for Gynecologic Malignancies]
[The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy].
[The mechanism of potentiation of the antitumor effect of 5-fluorouracil by methionine-free intravenous amino acid solution (AO-90) in rats]
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
[The role of vitamin B6 in tumor growth]
[The significance of measuring inhibition of thymidylate synthase activity as a parameter for antitumor activity of 5-fluorouracil derivatives]
[Theoretical basis for low-dose CDDP/5-FU therapy]
[Thymidylate synthase and dihydropyrimidine dehydrogenase activity in a metastatic liver tumor from colorectal cancer]
[Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients]
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method]
[Thymidylate synthase expression in patients with hypopharyngeal carcinoma]
[Thymidylate synthase inhibition and concentration of 5-fluorouracil after administration of UFT in human uroepithelial carcinomas]
[Thymidylate synthase inhibition in malignant tumors after oral administration of UFT]
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]
[UFT/CDDP preoperative chemotherapy for progressive gastric cancer--histological antitumor effects and thymidylate synthase inhibition rate]
Neoplastic Cells, Circulating
Molecular and Dynamic Evaluation of Proteins Related to Resistance to Neoadjuvant Treatment with Chemoradiotherapy in Circulating Tumor Cells of Patients with Locally Advanced Rectal Cancer.
Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients.
Neural Tube Defects
Thymidylate synthase repeat polymorphisms and risk of neural tube defects in a population from the northern United Kingdom.
Neuroblastoma
5,10-Methenyltetrahydrofolate synthetase activity is increased in tumors and modifies the efficacy of antipurine LY309887.
A comparison of thymidylate synthetase activities from 5-fluorodeoxyuridine sensitive and resistant variants of mouse neuroblastoma.
Altered thymidine kinase or thymidylate synthetase activities in 5-fluoro deoxyuridine resistant variants of mouse neuroblastoma.
Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5-fluorodeoxyuridine-resistant variant of mouse neuroblastoma.
Quinazoline antifolates as inhibitors of growth, dihydrofolate reductase, and thymidylate synthetase of mouse neuroblastoma cells in culture.
Regulation of the synthesis of choline-O-acetyltransferase and thymidylate synthetase in mouse neuroblastoma in cell culture.
Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines.
Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
Neuroectodermal Tumors
Thymidylate synthase 1 (ts1) in-situ protein expression predicts the survival of ewing/pnet.
Neuroendocrine Tumors
Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors.
Neutropenia
Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
Opportunistic Infections
Discovery of potent and selective inhibitors of Toxoplasma gondii thymidylate synthase for opportunistic infections.
Oropharyngeal Neoplasms
Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer.
Osteonecrosis
A Pharmacogenetic Study of VDR fok1 and TYMS Polymorphisms and Their Association With Glucocorticoid-Induced Osteonecrosis in Egyptian Children With Acute Lymphoblastic Leukemia.
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.
[Osteonecroses of the bilateral tali during maintenance therapy in a child with acute lymphoblastic leukemia]
Osteosarcoma
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.
Ovarian Neoplasms
A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer.
An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers.
Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.
Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.
Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase.
Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells.
Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth.
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations.
Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells.
Thymidylate synthase activity as a prognostic factor in ovarian cancer.
Paget Disease, Extramammary
Thymidylate synthase overexpression in extramammary Paget's disease.
Pancreatic Neoplasms
A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Accomplishments in 2007 in biologic markers for gastrointestinal cancers.
Alcohol drinking and one-carbon metabolism-related gene polymorphisms on pancreatic cancer risk.
Association of thymidylate synthase and hypoxia inducible factor-1alpha DNA polymorphisms with pancreatic cancer.
Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer.
Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer.
In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model.
Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine.
New approaches to the treatment of gastro-intestinal cancer.
Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy.
Third International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Cologne, 23-26 September 1998.
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?
Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer.
[Relationship between antitumor activity and the inhibition of thymidylate synthase after oral administration of UFT in nude mice bearing human tumor]
Pancreatitis
Association of Thymidylate Synthase Polymorphisms with Acute Pancreatitis and/or Peripheral Neuropathy in HIV-Infected Patients on Stavudine-Based Therapy.
Pancytopenia
Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism.
Papilloma
Suppression by kampo medicine, sho-saiko-to, on papillomas induced by 7,12-dimethylbenz(a)anthracene in mice.
Penile Neoplasms
Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.
[Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in penile cancer].
Peripheral Nervous System Diseases
Association of Thymidylate Synthase Polymorphisms with Acute Pancreatitis and/or Peripheral Neuropathy in HIV-Infected Patients on Stavudine-Based Therapy.
Peroneal Neuropathies
First Case of Foot Drop Associated with Capecitabine in a Patient with Thymidylate Synthase Polymorphism.
Placenta Diseases
Human trophoblast stem cells: Real or not real?
Pneumonia
Biodiversity of Pneumocystis carinii hominis: typing with different DNA regions.
The crystal structure of thymidylate synthase from Pneumocystis carinii reveals a fungal insert important for drug design.
Pneumonia, Pneumocystis
Biodiversity of Pneumocystis carinii hominis: typing with different DNA regions.
Inability of Pneumocystis organisms to incorporate bromodeoxyuridine suggests the absence of a salvage pathway for thymidine.
Pre-Eclampsia
ELF5-enforced transcriptional networks define an epigenetically regulated trophoblast stem cell compartment in the human placenta.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.
Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma.
beta-Carboline-benzoquinolizidine alkaloid deoxytubulosine inhibits thymidylate synthase activity in leukemic leukocytes from patients with chronic myeloblastic leukemia and acute lymphoblastic leukemia.
Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?
Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia.
Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Impact of thymidylate synthase promoter and DNA repair gene polymorphisms on susceptibility to childhood acute lymphoblastic leukemia.
Mechanisms of resistance to methotrexate in childhood acute lymphoblastic leukemia: circumvention of thymidylate synthase inhibition.
Messenger RNA expression of resistance factors and their correlation to the proliferative activity in childhood acute lymphoblastic leukemia.
Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL.
Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia.
The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
Thymidylate synthase activity in leukocytes from patients with chronic myelocytic leukemia and acute lymphocytic leukemia and its inhibition by phenanthroindolizidine alkaloids pergularinine and tylophorinidine.
Thymidylate synthase and methionine synthase polymorphisms are not associated with susceptibility to childhood acute lymphoblastic leukemia in Kurdish population from Western Iran.
Thymidylate synthase enhancer region polymorphism not related to susceptibility to acute lymphoblastic leukemia in the Kashmir population.
Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia.
TSER polymorphism is not associated with risk of pediatric acute lymphoblastic leukemia: A meta-analysis.
[Influence of thymidylate synthase gene polymorphisms on high-dose methotrexate-related toxicities in childhood acute lymphoblastic leukemia].
Pregnancy Complications
ELF5-enforced transcriptional networks define an epigenetically regulated trophoblast stem cell compartment in the human placenta.
Human trophoblast stem cells: Real or not real?
Presbycusis
Polymorphisms in folate metabolism genes are associated with susceptibility to presbycusis.
Primary Ovarian Insufficiency
Association of methylenetetrahydrofolate reductase (MTHFR 677C>T) and thymidylate synthase (TSER and TS 1494del6) polymorphisms with premature ovarian failure in Korean women.
Prostatic Neoplasms
Biomodulation of 5-Fu cytotoxicity by folinic acid and its stereoisomers: in vitro experiments with different cell lines of prostatic cancer.
Evaluation of Thymidylate Synthase Expression in Prostate Cancer.
Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.
High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase.
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Methionine restriction selectively targets thymidylate synthase in prostate cancer cells.
Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer.
Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.
The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
Rectal Neoplasms
A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy.
Correlation of spectral imaging and visual grading for the quantification of thymidylate synthase protein expression in rectal cancer.
EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer.
Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) and Microsatellite Instability in Patients with Colorectal Cancer and Its Clinical Features.
Enhancing chemoradiation of colorectal cancer through targeted delivery of raltitrexed by hyaluronic acid coated nanoparticles.
Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.
Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy.
High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.
High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer.
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
Immunohistochemical Markers as Predictors of Histopathologic Response and Prognosis in Rectal Cancer Treated with Preoperative Adjuvant Therapy: State of the Art.
Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors.
p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Pharmacogenetic Study in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy: Polymorphisms in Thymidylate Synthase, Epidermal Growth Factor Receptor, GSTP1, and DNA Repair Genes.
Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer.
Polymorphisms in the thymidylate synthase gene and risk of colorectal cancer.
Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
Preoperative Chemoradiation for Rectal Cancer Using Capecitabine and Celecoxib Correlated with Posttreatment Assessment of Thymidylate Synthase and Thymidine Phosphorylase Expression.
Pretreatment Expression of 13 Molecular Markers as a Predictor of Tumor Responses After Neoadjuvant Chemoradiation in Rectal Cancer.
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Prognostic Significance Of Thymidylate Synthase Polymorphisms In Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery.
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.
Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment.
Thymidylate synthase expression in rectal cancer and proliferation, assessed by cyclin A and Ki-67 expression.
Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer.
Thymidylate Synthase Gene Polymorphism Affects the Response to Preoperative 5-Fluorouracil Chemoradiation Therapy in Patients With Rectal Cancer.
Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.
Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
X-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer Patients.
[Neo-adjuvant chemotherapy with tegafur suppository for rectal cancer--evaluation of the antitumor effects, tissue levels of 5-FU and inhibition of thymidylate synthase. Tochigi Colorectal Cancer Study Group]
Relapsing Fever
Function and evolution of plasmid-borne genes for pyrimidine biosynthesis in Borrelia spp.
Retinoblastoma
Coordinated trans activation of DNA synthesis- and precursor-producing enzymes by polyomavirus large T antigen through interaction with the retinoblastoma protein.
Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases.
MTR polymorphic variant A2756G and retinoblastoma risk in Brazilian children.
Multiple molecular alterations in mouse lung tumors.
Sarcoma
Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Horse v-fes feline sarcoma viral oncogene homologue; pyruvate kinase, muscle type 2; plasminogen; beta spectrin, non-erythrocytic 1; thymidylate synthetase; and microsatellite LEX078 map to 1q14-q15, 1q21, 31q12-q14, 15q22, 8q12-q14, and 14q27, respectively.
Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.
Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells.
Prediction of antifolate efficacy in a rat sarcoma model.
Use of molecular biomarkers to inform adjuvant therapy for colon cancer.
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]
Sarcoma 180
Purification of thymidylate synthetase from enzyme-poor sources by affinity chromatography.
[The significance of measuring inhibition of thymidylate synthase activity as a parameter for antitumor activity of 5-fluorouracil derivatives]
Sarcoma, Kaposi
Human herpesvirus 8 gene encodes a functional thymidylate synthase.
Sarcoma, Yoshida
Schedule dependent inhibition of thymidylate synthase and tumor growth by 5-fluorouracil in Yoshida sarcoma bearing rats.
[Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil]
Sigmoid Neoplasms
Dependence of the thymidylate synthase inhibition rate on the interval after the last administration of tegafur in sigmoid colon cancer patients.
Skin Neoplasms
Intratumor dihydropyrimidine dehydrogenase mRNA expression levels are decreased in extramammary Paget's disease.
Small Cell Lung Carcinoma
Biochemical and pharmacologic rationale for high-dose methotrexate.
Smooth Muscle Tumor
PTEN, tau-AP-3, thymidylate synthase immunohistochemistry scoring expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignancy potential and uterine leiomyosarcomas.
Spinal Dysraphism
Associations between polymorphisms within the thymidylate synthase gene and spina bifida.
Squamous Cell Carcinoma of Head and Neck
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma.
Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
Characterization of the effect of AG337, a novel lipophilic thymidylate synthase inhibitor, on human head and neck and human leukemia cell lines.
Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.
Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma.
Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study.
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome.
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82.
One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: case-control study.
Predictive value of immunohistochemical thymidylate synthase expression for histological response to Tegafur/Uracil (UFT) in oral squamous cell carcinoma.
Relative level of thymidylate synthase mRNA expression in primary tumors and normal tissues predicts survival of patients with oral tongue squamous cell carcinoma.
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues.
Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study.
Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.
Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
Starvation
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Stomach Neoplasms
2R of Thymidylate Synthase 5'-untranslated Enhanced Region Contributes to Gastric Cancer Risk: a Meta-analysis.
3R Variant of Thymidylate Synthase 5'-untranslated Enhanced Region Contributes to Colorectal Cancer Risk: A Meta-analysis.
A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.
A predictive factor for the response to S-1 plus cisplatin in gastric cancer.
Activities of thymidylate synthetase and thymidine kinase in gastric cancer.
An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens.
Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.
Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastric cancer cells with or without p53 mutation.
Association between polymorphisms of thymidylate synthase gene 5'- and 3'-UTR and gastric cancer risk: meta-analysis.
Association of thymidylate synthase expression and clinical outcomes of gastric cancer patients treated with fluoropyrimidine-based chemotherapy: a meta-analysis.
Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.
Association of thymidylate synthase polymorphisms with gastric cancer susceptibility.
Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy.
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer.
Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer.
Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase.
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
Erratum to: Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy.
Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Expression of thymidylate synthase and thymidine phosphorylase in recurrence and survival rates of advanced gastric cancer.
Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy.
Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients.
Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
Expressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III ?-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin.
Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer.
Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer.
Histone chaperone CHAF1A impacts the outcome of fluoropyrimidines-based adjuvant therapy in gastric cancer by regulating the expression of thymidylate synthetase.
Histopathological response to preoperative chemotherapy including 5-fluorouracil additionally assessed by immunocytochemical and pharmacologic parameters in patients with advanced gastric cancer.
Human colorectal malignancy and oral UFT.
Immunohistochemical analysis of thymidylate synthase expression in gastric carcinoma: correlation with clinicopathological parameters and survival.
Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines.
Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy.
Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer.
Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Influence of TS (rs34743033) and RUNX1 (rs2014300) gene polymorphisms on survival outcomes of fluorouracil-based chemotherapy in Chinese advanced gastric cancer patients.
Intratumoral heterogeneous expression of thymidylate synthase in gastric cancer.
Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur.
Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Pharmacogenetics and stomach cancer: an update.
Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy.
Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer.
Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susceptibility to esophageal and stomach cancer with smoking.
Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Polymorphisms of thymidylate synthase gene 5'- and 3'-untranslated region and risk of gastric cancer in Koreans.
Polymorphisms of Thymidylate Synthase in the 5'- and 3'-Untranslated Regions and Gastric Cancer.
Polymorphisms of thymidylate synthase in the 5'- and 3'-untranslated regions associated with risk of gastric cancer in South China: a case-control analysis.
Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.
Predictive value of thymidylate synthase expression in gastric cancer: a systematic review with meta-analysis.
Prognostic evaluation of curatively resected locally advanced gastric cancer patients with preoperative downstaging chemotherapy assessed by histochemical and pharmacologic means.
Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy.
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy.
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: A pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.
Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.
Raltitrexed induces mitochondrial?mediated apoptosis in SGC7901 human gastric cancer cells.
Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer.
Relationship between the Expression of the Thymidylate Synthase and the Prognosis of Gastric Cancer Patients Treated with Combinational Chemotherapy Regimen Including Fluorouracil, Docetaxel and Cisplatin.
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.
Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer.
Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial.
The discrepancy in thymidylate synthase and dihydropyrimidine dehydrogenase expression depending on measurement methodologies in stage 4 gastric cancer.
The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer.
Thymidylate synthase (TS) mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.
Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer.
Thymidylate synthase and methylenetetrahy-drofolate reductase gene polymorphisms and gastric cancer susceptibility in a population of Northern Brazil.
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.
Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.
Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer.
Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.
Thymidylate Synthase Protein Expression
Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.
UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner.
[5-FU sensitivity and thymidylate synthase in gastric cancer]
[Clinical significance of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer]
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer]
[Effect of low dose CDDP/5-fluorouracil therapy on PCNA labeling index and TS inhibition rate of gastric cancer]
[Effect of low-dose CDDP/5-FU therapy on thymidylate synthase content]
[Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
[Interactions between lifestyle, methylanetetrahydrofolate reductase gene and polymorphisms in thymidylate synthase gene with risk of stomach cancer]
[The association of expression and gene polymorphism of the thymidylate synthase gene with 5-fluoro-5'-deoxyuridine sensitivity in gastric cancer cell lines]
[The expression of thymidylate synthase and thymidine phosphorylase in the early-stage of gastric cancer]
[The role of thymidylate synthetase in sequential dose of MTX and 5-FU in the advanced scirrhous type gastric cancer]
[Thymidine kinase and thymidylate synthetase activities in human gastric cancer]
[Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients]
[UFT/CDDP preoperative chemotherapy for progressive gastric cancer--histological antitumor effects and thymidylate synthase inhibition rate]
Stomatitis
Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation.
The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
Takotsubo Cardiomyopathy
The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes.
Thoracic Neoplasms
¹?F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
thymidylate synthase deficiency
Genetic analysis of two mutations affecting thymidine metabolism in Dictyostelium discoideum.
Isolation of functional cDNA clones for human thymidylate synthase.
Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency.
Thymoma
Expression of thymidylate synthase and orotate phosphoribosyltransferase in thymic carcinoma.
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma.
Thymus Neoplasms
Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors.
Tongue Neoplasms
Intratumoural expression of thymidylate synthase is an independent predictor of prognosis in patients with squamous cell carcinoma of the tongue: results from a retrospective study.
Trichinellosis
Binding and repression of translation of the cognate mRNA by Trichinella spiralis thymidylate synthase differ from the corresponding interactions of the human enzyme.
Triple Negative Breast Neoplasms
Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer.
Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy.
Tuberculosis
Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis.
Crystallization and preliminary crystallographic studies of a flavin-dependent thymidylate synthase from Helicobacter pylori.
dUMP/F-dUMP Binding to Thymidylate Synthase: Human Versus Mycobacterium tuberculosis.
Kinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX.
Mycobacterium tuberculosis thymidylate synthase (ThyX) is a target for plumbagin, a natural product with antimycobacterial activity.
Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid.
Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.
Synthesis and evaluation of C-5 modified 2'-deoxyuridine monophosphates as inhibitors of M. tuberculosis thymidylate synthase.
[Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis]
Urinary Bladder Neoplasms
Clinical significance of thymidylate synthase expression in bladder cancer.
Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects.
Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.
Expression of the fluoropyrimidine-metabolizing enzymes in bladder cancers as measured by the Danenberg tumor profile.
Polymorphisms in one-carbon metabolism pathway genes and risk for bladder cancer in a Tunisian population.
Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer.
Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells.
Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer.
Uterine Cervical Neoplasms
Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer.
Enhanced expression of thymidylate synthase mediates resistance of uterine cervical cancer cells to radiation.
Immunohistochemical investigation of thymidylate synthase in cervical cancer.
The HPV16 E6/E7 oncogene sensitizes human ovarian surface epithelial cells to low-dose but not high-dose 5-FU and 5-FUdR.
Thymidylate synthase inhibition as a predictor of tumor sensitivity of fluorinated pyrimidines.
[Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer]
Venous Thrombosis
Associations of common polymorphisms in the thymidylate synthase, reduced folate carrier and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase genes with folate and homocysteine levels and venous thrombosis risk.
Thymidylate synthase genotype and serum concentrations of homocysteine and folate in Behçet's disease.
Vitamin B 12 Deficiency
Evidence against defective thymidylate synthetase being the main biochemical lesion in vitamin B12 deficiency.
Vitamin B12--folate interrelations.
Xeroderma Pigmentosum
Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Pharmacogenetic Study in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy: Polymorphisms in Thymidylate Synthase, Epidermal Growth Factor Receptor, GSTP1, and DNA Repair Genes.